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1. 
ENGINEERED PRIMATE L-METHONNASE 
FOR THERAPEUTIC PURPOSES 
The present application claims the priority benefit of U.S. 
provisional application No. 61/871,768, filed Aug. 29, 2013, 
the entire contents of which are incorporated herein by 
reference. 
The invention was made with government Support under 
Grant No. R01 CA154754 awarded by the National Insti 
tutes of Health. The government has certain rights in the 
invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates generally to the fields of 
medicine and biology. More particularly, it concerns an 
improved human methionine-y-lyase (hMGL) for use in the 
treatment of cancer. 
2. Description of Related Art 
The demand for the essential amino acid, L-methionine, is 
exceptionally high in cancerous tissues. Depletion of 
methionine has been shown to be effective in killing a wide 
variety of tumor types without adversely affecting non 
cancerous tissues. Methionine depletion can be effected via 
the action of enzymes that hydrolyze the amino acid. While 
human methionine depleting enzymes did not previously 
exist, a bacterial enzyme from Pseudomonas aeruginosa, 
methionine-y-lyase, was shown to be therapeutically effec 
tive in the clinic and had been evaluated in clinical trials. 
However, methionine-y-lyase, being a bacterial protein, is 
highly immunogenic, eliciting the formation of specific 
antibodies, leading to adverse reactions and also reduced 
activity. Methionine-y-lyase also has a very short half-life of 
only about 2 h in vitro and in Vivo, necessitating very 
frequent and impractically high dosing to achieve systemic 
depletion. 
Systemic methionine depletion is the focus of much 
research and has the potential to treat cancers, such as 
metastatic breast cancer, prostate, neuroblastoma, and pan 
creatic carcinoma among others. Although there is much 
excitement for this therapeutic approach, the bacterially 
derived methionine-y-lyase has serious shortcomings (im 
munogenicity and rapid deactivation in serum, as discussed 
above) that greatly dampen enthusiasm for its use as a 
chemotherapeutic agent. 
Previously, an engineered human methionine-y-lyase 
(hMGL-NLV) was created by introducing three key amino 
acid substitutions in the human enzyme cystathionine-y- 
lyase (CGL): E59N, R119L, E339V. See, U.S. Pat. No. 
8,709,407, which is incorporated herein by reference. Unlike 
native CGIL, which displays essentially no catalytic activity 
towards L-methionine, the E59N, R119L, E339V variant 
enzyme (hMGL-NLV) displays robust L-methionine 
degrading activity in vivo and in vitro. Nonetheless, there 
remains a need to develop human L-methionine degrading 
enzymes with higher catalytic activity so that a therapeutic 
effect can be attained with lower dosing and/or less frequent 
administration of the enzyme. 
SUMMARY OF THE INVENTION 
Provided herein are human methionine-y-lyase (hMGL) 
mutants with higher catalytic activity than hMGL-NLV. The 
preferred improved hMGL proteins exhibit 6-10 fold higher 
activity. Due to the higher catalytic activity, the provided 














methionine depletion and thus lower concentrations of thera 
peutic agent may be required for dosing of patients. This 
enzyme was engineered by introducing amino acid Substi 
tutions in the human enzyme cystathionine-y-lyase (CGL) at 
positions comprising residues E59, R119, or E339. In one 
particular embodiment, preferred substitutions of E59, 
R119, and E339 in hCGL include, respectively, L-asparagine 
(at position 59), L-leucine (at position 119) and L-valine (at 
position 339). The present invention discloses compositions 
of matter displaying higher catalytic activity relative to the 
hMGL-NLV variants. These contain substitutions at least at 
two of the E59, R119, or E339 positions identified as critical 
for conferring L-methionine-y-lyase activity compared to 
the hMGL-NLV variants. The higher catalytic activity of 
these variants is important because lower concentrations of 
therapeutic agent may be required for dosing of patients. 
The variants having additional amino acid Substitutions 
include SEQ ID NO: 3, hCGL-E59N-S63L-L91M-R119L 
K268R-T311G-E339V-I353S (hCGL-8mut-1); SEQID NO: 
4, hCGL-E59I-S63L-L91 M-R119L-K268R-T311G-E339V 
I353S (hCGL-8mut-2); SEQID NO: 5, hCGL-E59N-S63L 
L91M-R119A-K268R-T311G-E339V-I353S (hCGL-8mut 
3); and SEQ ID NO: 6, hCGL-E59I-S63L-L91M-R119A 
K268R-T311G-E339V-I353S (hCGL-8mut-4). 
Certain aspects of the present invention overcome a major 
deficiency in the art by providing improved enzymes that 
comprise human polypeptide sequences having methionine 
y-lyase (MGL) activity, which may be suitable for cancer 
therapy and have low immunogenicity, improved serum 
stability, and improved catalytic activity. Accordingly, in a 
first embodiment there is provided a modified polypeptide 
(i.e., enzyme), particularly an enzyme variant with methio 
nine-degrading activity derived from primate enzymes 
related to MGL. For example, the novel enzyme variant may 
have an amino acid sequence selected from the group 
consisting of SEQ ID NOs: 3-6. In particular, the variant 
may be derived from human enzymes, such as human 
cyStathionine-y-lyase (CGL). In certain aspects, there may 
be a polypeptide comprising a modified human CGL capable 
of degrading methionine. In some embodiments, the poly 
peptide may be capable of degrading methionine under 
physiological conditions. For example, the polypeptide may 
have a catalytic efficiency for methionine (k/K) of at 
least or about 0.01, 0.05, 0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 
0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 
100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 
3000, 4000, 5000, 6000, 7000, 8000, 9000, 10, 10, 10° 
M's or any range derivable therein. In further aspects, the 
polypeptide may display a catalytic activity towards L-ho 
mocystine up to k/K of 100, 95, 90, 85, 80, 75, 70, 65, 
60,55, 50, 45, 40, 35, 30, 25, 20, 15, 10,9,8, 7, 6, 5, 4, 3, 
2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05, 0.01, 
0.005, 0.001 M's or any range derivable therein. 
A modified polypeptide as discussed above may be char 
acterized as having a certain percentage of identity as 
compared to an unmodified polypeptide (e.g., a native 
polypeptide) or to any polypeptide sequence disclosed 
herein. For example, the unmodified polypeptide may com 
prise at least or up to about 10, 20, 30, 40, 50, 60, 70, 80,90, 
100, 150, 200, 250, 300, 350, 400 residues (or any range 
derivable therein) of a native primate cyStathionase (i.e., 
cyStathionine-y-lyase). The percentage identity may be 
about, at most or at least 50%, 55%, 60%. 65%, 70%, 75%, 
80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or 
any range derivable therein) between the unmodified por 
tions of a modified polypeptide (i.e., the sequence of the 
modified polypeptide excluding any Substitutions at amino 
US 9,481,877 B2 
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acid positions 59, 63,91, 119, 268, 311,339 and/or 353) and 
the native polypeptide. It is also contemplated that the 
percent identity discussed above may relate to a particular 
modified region of a polypeptide as compared to an unmodi 
fied region of a polypeptide. For instance, a polypeptide may 
contain a modified or mutant Substrate recognition site of 
cyStathionase that can be characterized based on the identity 
of the amino acid sequence of the modified or mutant 
Substrate recognition site of cystathionase to that of an 
unmodified or mutant cystathionase from the same species 
or across the species. A modified or mutant human poly 
peptide characterized, for example, as having at least 90% 
identity to an unmodified cystathionase means that at least 
90% of the amino acids in that modified or mutant human 
polypeptide are identical to the amino acids in the unmodi 
fied polypeptide. 
Such an unmodified polypeptide may be a native cysta 
thionase, particularly a human isoform or other primate 
isoforms. For example, the native human cyStathionase may 
have the sequence of SEQID NO: 1. Non-limiting examples 
of other native primate cystathionases include Pongo abelii 
cystathionase (Genbank ID: NP_001 124635.1: SEQID NO: 
7), Macaca fascicularis cystathionase (Genbank ID: 
AAW71993.1: SEQ ID NO: 8), Pan troglodytes cystathio 
nase (Genbank ID: XP 513486.2: SEQID NO:9), and Pan 
paniscus cystathionase (Genbank ID: XP 00383.0652.1; 
SEQ ID NO: 10). Exemplary native polypeptides include a 
sequence having about, at most or at least 50%, 55%, 60%, 
65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 
99% or 100% identity (or any range derivable therein) of 
SEQID NOs: 1 or 7-10 or a fragment thereof. For example, 
the native polypeptide may comprise at least or up to about 
10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 
350, 400, 415 residues (or any range derivable therein) of the 
sequence of SEQ ID NOs: 1 or 7-10. 
In some embodiments, the native CGL may be modified 
by one or more other modifications, such as chemical 
modifications, Substitutions, insertions, deletions, and/or 
truncations. For example, the modifications may be at a 
Substrate recognitions site of the native enzyme. In a par 
ticular embodiment, the native CGL may be modified by 
substitutions. For example, the number of substitutions may 
be four, five, six, seven, or more. In further embodiments, 
the native CGL may be modified in the substrate recognition 
site or any location that may affect substrate specificity. For 
example, the modified polypeptide may have the at least one 
amino acid substitution at amino acid positions correspond 
ing to E59, S63, L91, R119, K268, T311, E339, and/or I353 
of SEQID NO: 1 or amino acid positions of 59, 63,91, 119, 
268, 311,339, and/or 353 of a primate CGL. For example, 
the primate may be human, Pongo abelii, Macaca fascicu 
laris, Pan troglodyte, or Pan paniscus. 
In certain embodiments, the Substitutions at amino acid 
positions 59, 63, 91, 119, 268, 311, 339, and/or 353 is an 
aspartic acid (N), a valine (V), a leucine (L), a methionine 
(M), an arginine (R), a glycine (G), an alanine (A), or a 
serine (S). In particular embodiments, the modification are 
one or more substitutions selected from the group consisting 
of E59N, E59I, S63L, L91M, R119L, R119A, K268R, 
T311G, E339V, and I353S. In a further embodiment, the 
substitutions may comprise a S63L. L91M, K268R, T311G, 
E339V, and I353S substitutions. In a still further embodi 
ment, the Substitutions may comprise additional Substitu 
tions of either E59N or E59I and either R119L or R119A. 
In some embodiments, the native CGL may be a human 
CGL. In a particular embodiment, the substitutions are a 














T311G, I353S, and E339V of human CGL (for example, the 
modified polypeptide having the amino acid sequence of 
SEQ ID NO: 3, a fragment or homolog thereof), a combi 
nation of E59I, S63L, L91M, R119L, K268R, T311G, 
I353S, E339V of human CGL (for example, the modified 
polypeptide having the amino acid sequence of SEQID NO: 
4, a fragment or homolog thereof), a combination of E59N, 
S63L, L91M, R119A, K268R, T311G, I353S, and E339V of 
human CGL (for example, the modified polypeptide having 
the amino acid sequence of SEQ ID NO: 5, a fragment or 
homolog thereof), or a combination of E59I, S63L, L91M, 
R119A, K268R, T311G, I353S, and E339V of human CGL 
(for example, the modified polypeptide having the amino 
acid sequence of SEQ ID NO: 6, a fragment or homolog 
thereof). In a further embodiment, the modified polypeptide 
may be a Pongo abelii CGL-NLMLRGSV mutant (SEQ ID 
NO: 11), Pongo abelii CGL-ILMLRGSV mutant (SEQ ID 
NO: 12), Pongo abelii CGL-NLMARGSV mutant (SEQ ID 
NO: 13), Pongo abelii CGL-ILMARGSV mutant (SEQ ID 
NO: 14), Macaca fascicularis CGL-NLMLRGSV mutant 
(SEQ ID NO: 15), Macaca fascicularis CGL-ILMLRGSV 
mutant (SEQ ID NO: 16), Macaca fascicularis CGL-NL 
MARGSV mutant (SEQ ID NO: 17), Macaca fascicularis 
CGL-ILMARGSV mutant (SEQ ID NO: 18), Pan troglo 
dytes CGL-NLMLRGSV mutant (SEQ ID NO: 19), Pan 
troglodytes CGL-ILMLRGSV mutant (SEQ ID NO: 20), 
Pan troglodytes CGL-NLMARGSV mutant (SEQ ID NO: 
21), Pan troglodytes CGL-ILMARGSV mutant (SEQ ID 
NO: 22), Pan paniscus CGL-NLMLRGSV mutant (SEQ ID 
NO. 23), Pan paniscus CGL-ILMLRGSV mutant (SEQ ID 
NO: 24), Pan paniscus CGL-NLMARGSV mutant (SEQ ID 
NO: 25), or Pan paniscus CGL-ILMARGSV mutant (SEQ 
ID NO: 26). 
In some aspects, the present invention also contemplates 
polypeptides comprising the modified CGL linked to a 
heterologous amino acid sequence. For example, the modi 
fied CGL may be linked to the heterologous amino acid 
sequence as a fusion protein. In a particular embodiment, the 
modified CGL may be linked to amino acid sequences. Such 
as an IgG Fc, albumin, an albumin binding peptide, or an 
XTEN polypeptide for increasing the in vivo half-life. 
To increase serum stability, the modified CGL may be 
linked to one or more polyether molecules. In a particular 
embodiment, the polyether may be polyethylene glycol 
(PEG). The modified polypeptide may be linked to PEG via 
specific amino acid residues, such as lysine or cysteine. For 
therapeutic administration, such a polypeptide comprising 
the modified CGL may be dispersed in a pharmaceutically 
acceptable carrier. 
In some aspects, a nucleic acid encoding Such a modified 
CGL is contemplated. In some embodiments, the nucleic 
acid has been codon optimized for expression in bacteria. In 
particular embodiments, the bacteria is E. coli. In other 
aspects, the nucleic acid has been codon optimized for 
expression in fungus (e.g., yeast), insects, or mammals. The 
present invention further contemplates vectors, such as 
expression vectors, containing such nucleic acids. In par 
ticular embodiments, the nucleic acid encoding the modified 
CGL is operably linked to a promoter, including but not 
limited to heterologous promoters. In one embodiment, a 
modified CGL may be delivered to a target cell by a vector 
(e.g., a gene therapy vector). Such viruses may have been 
modified by recombinant DNA technology to enable the 
expression of the modified CGL-encoding nucleic acid in 
the target cell. These vectors may be derived from vectors of 
non-viral (e.g., plasmids) or viral (e.g., adenovirus, adeno 
associated virus, retrovirus, lentivirus, herpes virus, or vac 
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cinia virus) origin. Non-viral vectors are preferably com 
plexed with agents to facilitate the entry of the DNA across 
the cellular membrane. Examples of such non-viral vector 
complexes include the formulation with polycationic agents, 
which facilitate the condensation of the DNA and lipid 
based delivery systems. An example of a lipid-based deliv 
ery system would include liposome based delivery of 
nucleic acids. 
In still further aspects, the present invention further con 
templates host cells comprising Such vectors. The host cells 
may be bacteria (e.g., E. coli), fungal cells (e.g., yeast), 
insect cells, or mammalian cells. To further differentiate 
desired CGL mutants with methionine degrading activity 
from the native CGL, host cells having deletions of ilvA and 
metA (e.g., E. coli ilvA metA) may be prepared and used 
to identify desired mutants. 
In some embodiments, the vectors are introduced into 
host cells for expressing the modified CGIL. The proteins 
may be expressed in any suitable manner. In one embodi 
ment, the proteins are expressed in a host cell Such that the 
protein is glycosylated. In another embodiment, the proteins 
are expressed in a host cell Such that the protein is aglyco 
Sylated. 
Certain aspects of the present invention also contemplate 
methods of treatment by the administration of the modified 
CGL peptide, the nucleic acid encoding the modified CGL 
in a gene therapy vector, or the formulation of the present 
invention, and in particular methods of treating tumor cells 
or subjects with cancer. The Subject may be any animal. Such 
as a mouse. For example, the Subject may be a mammal, 
particularly a primate, and more particularly a human 
patient. In some embodiments, the method may comprise 
selecting a patient with cancer. In certain aspects, the Subject 
or patient may be maintained on a methionine-restricted diet 
or a normal diet. 
In some embodiments, the cancer is any cancer that is 
sensitive to methionine depletion. In one embodiment, the 
present invention contemplates a method of treating a tumor 
cell or a cancer patient comprising administering a formu 
lation comprising such a polypeptide. In some embodi 
ments, the administration occurs under conditions such that 
at least a portion of the cells of the cancer are killed. In 
another embodiment, the formulation comprises such a 
modified CGL with methionine degrading activity at physi 
ological conditions and further comprising an attached poly 
ethylene glycol chain. In some embodiment, the formulation 
is a pharmaceutical formulation comprising any of the above 
discussed CGL variants and pharmaceutically acceptable 
excipients. Such pharmaceutically acceptable excipients are 
well known to those of skill in the art. All of the above CGL 
variants may be contemplated as useful for human therapy. 
In a further embodiment, there may also be provided a 
method of treating a tumor cell comprising administering a 
formulation comprising a non-bacterial (mammalian, e.g., 
primate or mouse) modified CGL that has methionine 
degrading activity or a nucleic acid encoding thereof. 
Because tumor cells are dependent upon their nutrient 
medium for methionine, the administration or treatment may 
be directed to the nutrient source for the cells, and not 
necessarily the cells themselves. Therefore, in an in vivo 
application, treating a tumor cell includes contacting the 
nutrient medium for a population of tumor cells with the 
engineered methioninase. In this embodiment, the medium 
can be blood, lymphatic fluid, spinal fluid and the like bodily 
fluid where methionine depletion is desired. 
In accordance with certain aspects of the present inven 













ninase can be administered intravenously, intradermally, 
intraarterially, intraperitoneally, intralesionally, intracrani 
ally, intraarticularly, intraprostatically, intrapleurally, intra 
synovially, intratracheally, intranasally, intravitreally, intra 
vaginally, intrarectally, intratumorally, intramuscularly, 
Subcutaneously, Subconjunctival, intravesicularly, 
mucosally, intrapericardially, intraumbilically, intraocularly, 
orally, topically, by inhalation, infusion, continuous infu 
Sion, localized perfusion, via a catheter, via a lavage, in lipid 
compositions (e.g., liposomes), or by other method or any 
combination of the forgoing as would be known to one of 
ordinary skill in the art. 
In a further embodiment, the method may also comprise 
administering at least a second anticancer therapy to the 
Subject. The second anticancer therapy may be a Surgical 
therapy, chemotherapy, radiation therapy, cryotherapy, hor 
mone therapy, immunotherapy or cytokine therapy. 
In one embodiment, a composition comprising an engi 
neered methioninase or a nucleic acid encoding an engi 
neered methioninase is provided for use in the treatment of 
a tumor in a Subject. In another embodiment, the use of an 
engineered methioninase or a nucleic acid encoding an 
engineered methioninase in the manufacture of a medica 
ment for the treatment of a tumor is provided. Said engi 
neered methioninase may be any engineered methioninase 
of the embodiments. 
Embodiments discussed in the context of methods and/or 
compositions of the invention may be employed with respect 
to any other method or composition described herein. Thus, 
an embodiment pertaining to one method or composition 
may be applied to other methods and compositions of the 
invention as well. 
As used herein the terms “encode' or “encoding, with 
reference to a nucleic acid, are used to make the invention 
readily understandable by the skilled artisan; however, these 
terms may be used interchangeably with “comprise' or 
“comprising.” respectively. 
As used herein the specification, “a” or “an may mean 
one or more. As used herein in the claim(s), when used in 
conjunction with the word “comprising, the words “a” or 
'an' may mean one or more than one. 
The use of the term 'or' in the claims is used to mean 
“and/or unless explicitly indicated to refer to alternatives 
only or the alternatives are mutually exclusive, although the 
disclosure Supports a definition that refers to only alterna 
tives and “and/or.” As used herein “another may mean at 
least a second or more. 
Throughout this application, the term “about is used to 
indicate that a value includes the inherent variation of error 
for the device, the method being employed to determine the 
value, or the variation that exists among the study Subjects. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indi 
cating preferred embodiments of the invention, are given by 
way of illustration only, since various changes and modifi 
cations within the spirit and scope of the invention will 
become apparent to those skilled in the art from this detailed 
description. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
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combination with the detailed description of specific 
embodiments presented herein. 
FIG. 1—Sequence alignment of hCGL with hCGL-8mut 
1-4. Highlighted residues indicate mutated residues and their 
position. hCGL=SEQ ID NO: 1; hCGL-8mut-1=SEQ ID 
NO: 3; hCGL-8mut-2-SEQID NO: 4; hoGL-8mut-3=SEQ 
ID NO: 5; and hCGL-8mut-4=SEQ ID NO: 6. 
FIG. 2. The effect on prostate tumor cell lines PC3 (open 
circle) and DU145 (solid square) treated with titrations of 
hCGL-8mut-1 resulting with apparent ICs values of 0.25 
uM and 0.21 uM, respectively. 
FIG. 3 Activity of PEGylated hCGL-8mut-1 incubated 
in pooled human serum at 37° C. as a function of time: 
Apparent Tos-100+4 h. 
FIG. 4.—A single dose of PEG-hCGL-8mut-1 can lower 
serum L-methionine to therapeutically relevant levels for 
over 15 h without dietary intervention in a mouse model. 
FIG. 5 Comparison of single doses of 200 mg/kg PEG 
hCGL-NLV (open square) and 50 mg/kg PEG-hCGL 
8mut-1 (open circle) in reducing serum L-methionine in 
mice on a normal diet. 
DESCRIPTION OF ILLUSTRATIVE 
EMBODIMENTS 
The present invention discloses compositions of matter 
for improved human methionine-y-lyase (hMGL) relative to 
the hMGL-NLV mutant (E59N, R119L, E339V). These 
mutants display higher catalytic activity and thus lower 
concentrations of therapeutic agent may be required for 
dosing of patients. These engineered human enzymes 
degrade the amino acid L-methionine. 
These compositions provide a way to specifically target 
tumor cells through a cancer-specific metabolic defect. 
While bacterial enzymes can also perform the chemistry, 
their use has proven highly unstable and immunogenic. 
I. DEFINITIONS 
As used herein the terms “protein’ and “polypeptide' 
refer to compounds comprising amino acids joined via 
peptide bonds and are used interchangeably. 
As used herein, the term “fusion protein’ refers to a 
chimeric protein containing proteins or protein fragments 
operably linked in a non-native way. 
As used herein, the term “half-life' (/2-life) refers to the 
time that would be required for the concentration of a 
polypeptide thereof to fall by half in vitro or in vivo, for 
example, after injection in a mammal. 
The terms “in operable combination,” “in operable order.” 
and “operably linked refer to a linkage wherein the com 
ponents so described are in a relationship permitting them to 
function in their intended manner, for example, a linkage of 
nucleic acid sequences in Such a manner that a nucleic acid 
molecule capable of directing the transcription of a given 
gene and/or the synthesis of desired protein molecule, or a 
linkage of amino acid sequences in Such a manner so that a 
fusion protein is produced. 
The term “linker' is meant to refer to a compound or 
moiety that acts as a molecular bridge to operably link two 
different molecules, wherein one portion of the linker is 
operably linked to a first molecule, and wherein another 
portion of the linker is operably linked to a second molecule. 
The term "PEGylated’ refers to conjugation with poly 
ethylene glycol (PEG), which has been widely used as a 
drug carrier, given its high degree of biocompatibility and 













linked) to active agents through the hydroxy groups at the 
end of the PEG chain via chemical methods; however, PEG 
itself is limited to at most two active agents per molecule. In 
a different approach, copolymers of PEG and amino acids 
have been explored as novel biomaterial that would retain 
the biocompatibility of PEG, but that would have the added 
advantage of numerous attachment points per molecule (thus 
providing greater drug loading), and that can be syntheti 
cally designed to Suit a variety of applications. 
The term “gene’ refers to a DNA sequence that comprises 
control and coding sequences necessary for the production 
of a polypeptide or precursor thereof. The polypeptide can 
be encoded by a full-length coding sequence or by any 
portion of the coding sequence So as the desired enzymatic 
activity is retained. 
The term “native' refers to the typical form of a gene, a 
gene product, or a characteristic of that gene or gene product 
when isolated from a naturally occurring source. A native 
form is that which is most frequently observed in a natural 
population and is thus arbitrarily designated the normal or 
wild-type form. In contrast, the term “modified,” “variant.” 
or “mutant refers to a gene or gene product that displays 
modification in sequence and functional properties (i.e., 
altered characteristics) when compared to the native gene or 
gene product. 
The term “vector” is used to refer to a carrier nucleic acid 
molecule into which a nucleic acid sequence can be inserted 
for introduction into a cell where it can be replicated. A 
nucleic acid sequence can be “exogenous,” which means 
that it is foreign to the cell into which the vector is being 
introduced or that the sequence is homologous to a sequence 
in the cell but in a position within the host cell nucleic acid 
in which the sequence is ordinarily not found. Vectors 
include plasmids, cosmids, viruses (bacteriophage, animal 
viruses, and plant viruses), and artificial chromosomes (e.g., 
YACs). One of skill in the art would be well equipped to 
construct a vector through standard recombinant techniques 
(see, for example, Maniatis et al., 1988 and Ausubel et al., 
1994, both incorporated herein by reference). 
The term “expression vector” refers to any type of genetic 
construct comprising a nucleic acid coding for an RNA 
capable of being transcribed. In some cases, RNA molecules 
are then translated into a protein, polypeptide, or peptide. In 
other cases, these sequences are not translated, for example, 
in the production of antisense molecules or ribozymes. 
Expression vectors can contain a variety of "control 
sequences,” which refer to nucleic acid sequences necessary 
for the transcription and possibly translation of an operably 
linked coding sequence in a particular host cell. In addition 
to control sequences that govern transcription and transla 
tion, vectors and expression vectors may contain nucleic 
acid sequences that serve other functions as well and are 
described infra. 
The term “therapeutic benefit’ or “therapeutically effec 
tive' as used throughout this application refers to anything 
that promotes or enhances the well-being of the subject with 
respect to the medical treatment of this condition. This 
includes, but is not limited to, a reduction in the frequency 
or severity of the signs or symptoms of a disease. For 
example, treatment of cancer may involve, for example, a 
reduction in the size of a tumor, a reduction in the invasive 
ness of a tumor, reduction in the growth rate of the cancer, 
or prevention of metastasis. Treatment of cancer may also 
refer to prolonging Survival of a Subject with cancer. 
The term “K as used herein refers to the Michaelis 
Menten constant for an enzyme and is defined as the 
concentration of the specific Substrate at which a given 
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enzyme yields one-half its maximum velocity in an enzyme 
catalyzed reaction. The term “k, as used herein refers to 
the turnover number or the number of substrate molecules 
each enzyme site converts to product per unit time, and in 
which the enzyme is working at maximum efficiency. The 
term "k/K as used herein is the specificity constant, 
which is a measure of how efficiently an enzyme converts a 
Substrate into product. 
The term "cystathionine-y-lyase' (CGL or cystathionase) 
refers to any enzyme that catalyzes the hydrolysis of cys 
tathionine to cysteine. For example, it includes primate 
forms of cystathionine-y-lyase, or particularly, human forms 
of cystathionine-y-lyase. 
“Treatment” and “treating refer to administration or 
application of a therapeutic agent to a subject or perfor 
mance of a procedure or modality on a subject for the 
purpose of obtaining a therapeutic benefit of a disease or 
health-related condition. For example, a treatment may 
include administration of a pharmaceutically effective 
amount of a methioninase. 
“Subject' and “patient” refer to either a human or non 
human, Such as primates, mammals, and vertebrates. In 
particular embodiments, the Subject is a human. 
II. METHIONINE-y-LYASE AND 
CYSTATHIONINE-Y-LYASE 
A lyase is an enzyme that catalyzes the breaking of 
various chemical bonds, often forming a new double bond or 
a new ring structure. For example, an enzyme that catalyzes 
this reaction would be a lyase: ATP->cAMP-PPi. Lyases 
differ from other enzymes in that they only require one 
substrate for the reaction in one direction, but two substrates 
for the reverse reaction. 
A number of pyrioxal-5'-phosphate (PLP)-dependent 
enzymes are involved in the metabolism of cysteine, homo 
cysteine, and methionine, and these enzymes form an evo 
lutionarily related family, designated as Cys/Met metabo 
lism PLP-dependent enzymes. These enzymes are proteins 
of about 400 amino acids and the PLP group is attached to 
a lysine residue located in the central location of the poly 
peptide. Members of this family include cystathionine-y- 
lyase (CGL), cystathionine-y-Synthase (CGS), cystathio 
nine-3-lyase (CBL), methionine-y-lyase (MGL), and 
O-acetylhomoserine (OAH)/O-acetyl-serine (OAS) sulfhy 
drylase (OSHS). Common to all of them is the formation of 
a Michaelis complex leading to an external Substrate 
aldimine. The further course of the reaction is determined by 
the Substrate specificity of the particular enzyme. 
For example, the inventors introduced specific mutations 
into a PLP-dependent lyase family member, such as the 
human cyStathionine-y-lyase, to change its Substrate speci 
ficity. In this manner the inventors produced novel variants 
with the de novo ability to degrade L-Met as a substrate with 
substantially higher catalytic activity than hMGL-NLV. In 
other embodiments, a modification of other PLP-dependent 
enzymes for producing novel methionine degrading activity 
may also be contemplated. 
As a PLP-dependent enzyme, a methionine-y-lyase (EC 
4.4.1.11) is an enzyme that catalyzes the chemical reaction: 
L-methionine--HO->methanethiol--NH+2-oxobutanoate. 
Thus, the two substrates of this enzyme are L-methionine 
and HO, whereas its three products are methanethiol, NH, 
and 2-oxobutanoate. This enzyme belongs to the family of 
lyases, specifically the class of carbon-sulfur lyases. The 
systematic name of this enzyme class is L-methionine 













Other names in common use include L-methioninase, 
methionine lyase, methioninase, methionine dethiomethyl 
ase, L-methionine-gamma-lyase, and L-methionine meth 
anethiol-lyase (deaminating). This enzyme participates in 
Selenoamino acid metabolism. It employs one cofactor, 
pyridoxal-5'-phosphate. 
Methioninase usually consists of 389-441 amino acids 
and forms a homotetramer. Methioninase enzymes are gen 
erally composed of four identical subunits of molecular 
weight of ~45 kDa (Sridhar et al., 2000; Nakamura et al., 
1984). The structure of the enzyme was elucidated by 
crystallization (Kudou et al., 2007). Each segment of the 
tetramer is composed of three regions: an extended N-ter 
minal domain (residues 1-63) that includes two helices and 
three beta-strands, a large PLP binding domain (residues 
64-262) that is made up of a mostly parallel seven stranded 
beta-sheet that is sandwiched between eight alpha-helices, 
and a C-terminal domain (residues 263-398). The cofactor 
PLP is required for catalytic function. Amino acids impor 
tant for catalysis have been identified based on the structure. 
TyrS9 and Argé1 of neighboring subunits, which are also 
strongly conserved in other c-family enzymes, contact the 
phosphate group of PLP. These residues are important as the 
main anchor within the active site. Lys240, Asp241, and 
Arg61 of one monomer and Tyr114 and Cys116 of an 
adjacent monomer form a hydrogen-bond network in the 
methioninase active site that confers specificity to the 
enzyme. 
CyStathionine-y-lyase (CGL or cyStathionase) is an 
enzyme that breaks down cystathionine into cysteine and 
C.-ketobutyrate. Pyridoxal phosphate is a prosthetic group of 
this enzyme. Although mammals do not have a methioninase 
(MGL), they do have cyStathionase with sequence, struc 
tural, and chemical homology to the bacterial MGL 
enzymes. As shown in the Examples, protein engineering 
was used to convert cyStathionase, which has no activity for 
the degradation of L-Methionine, into an enzyme that can 
degrade this amino acid at a high rate. 
III. METHIONINASE ENGINEERING 
Since humans do not produce methionine-y-lyase (MGL 
or methioninase) it is necessary to engineer methioninases 
for human therapy that have high activity and specificity for 
degrading methionine under physiological conditions, as 
well as high stability in physiological fluids, such as serum, 
and are also non-immunogenic because they are native 
proteins that normally elicit immunological tolerance. 
Due to the undesired immunogenic effects seen in animal 
studies with plvGL (MGL from P. putida), it is desirable to 
engineer L-methionine degradation activity in a human 
enzyme. Immunological tolerance to human proteins makes 
it likely that such an enzyme will be non-immunogenic or 
minimally immunogenic and therefore well tolerated. 
Certain aspects of novel enzymes with MGL activity as 
engineered methioninase address these needs. Although 
mammals do not have a MGL, they do have a cyStathionine 
y-lyase (CGL) that has sequence, structural, and chemical 
homology to the bacterial MGL enzymes. CGL is a tetramer 
that catalyzes the last step in the mammalian transsulfuration 
pathway (Rao et al., 1990). CGL catalyzes the conversion of 
L-cystathionine to L-cysteine, alpha-ketobutyrate, and 
ammonia. The human CGL (hCGL) cDNA had previously 
been cloned and expressed, but with relatively low yields 
(-5 mg/L culture) (Lu et al., 1992; Steegborn et al., 1999). 
For example, there have been provided methods and 
compositions related to a primate (particularly human) cys 
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tathionine-y-lyase (CGL or cystathionase) modified via 
mutagenesis to hydrolyze methionine with high efficiency, 
while the cystathionine-y-lyase does not exhibit methioni 
nase activity in its native form. 
Some embodiments concern modified proteins and poly 
peptides. Particular embodiments concern a modified pro 
tein or polypeptide that exhibits at least one functional 
activity that is comparable to the unmodified version, pref 
erably, the methioninase enzyme activity. In further aspects, 
the protein or polypeptide may be further modified to 
increase serum stability. Thus, when the present application 
refers to the function or activity of “modified protein’ or a 
“modified polypeptide, one of ordinary skill in the art 
would understand that this includes, for example, a protein 
or polypeptide that possesses an additional advantage over 
the unmodified protein or polypeptide. Such as the methio 
ninase enzyme activity. In certain embodiments, the 
unmodified protein or polypeptide is a native cyStathionine 
y-lyase, specifically a human cyStathionine-y-lyase. It is 
specifically contemplated that embodiments concerning a 
“modified protein’ may be implemented with respect to a 
“modified polypeptide,” and vice versa. 
Determination of activity may be achieved using assays 
familiar to those of skill in the art, particularly with respect 
to the protein's activity, and may include for comparison 
purposes, for example, the use of native and/or recombinant 
versions of either the modified or unmodified protein or 
polypeptide. For example, the methioninase activity may be 
determined by any assay to detect the production of any 
Substrates resulting from conversion of methionine, such as 
alpha-ketobutyrate, methanethiol, and/or ammonia. 
In certain embodiments, a modified polypeptide, such as 
a modified cystathionine-y-lyase, may be identified based on 
its increase in methionine degrading activity. For example, 
Substrate recognition sites of the unmodified polypeptide 
may be identified. This identification may be based on 
structural analysis or homology analysis. A population of 
mutants involving modifications of Such substrate recogni 
tions sites may be generated. In a further embodiment, 
mutants with increased methionine degrading activity may 
be selected from the mutant population. Selection of desired 
mutants may include methods, such as detection of byprod 
ucts or products from methionine degradation. 
Modified proteins may possess deletions and/or substitu 
tions of amino acids; thus, a protein with a deletion, a protein 
with a substitution, and a protein with a deletion and a 
Substitution are modified proteins. In some embodiments, 
these modified proteins may further include insertions or 
added amino acids, Such as with fusion proteins or proteins 
with linkers, for example. A “modified deleted protein' lacks 
one or more residues of the native protein, but may possess 
the specificity and/or activity of the native protein. A “modi 
fied deleted protein' may also have reduced immunogenicity 
or antigenicity. An example of a modified deleted protein is 
one that has an amino acid residue deleted from at least one 
antigenic region, that is, a region of the protein determined 
to be antigenic in a particular organism, such as the type of 
organism that may be administered the modified protein. 
Substitution or replacement variants typically contain the 
exchange of one amino acid for another at one or more sites 
within the protein and may be designed to modulate one or 
more properties of the polypeptide, particularly its effector 
functions and/or bioavailability. Substitutions may or may 
not be conservative, that is, one amino acid is replaced with 
one of similar shape and charge. Conservative Substitutions 
are well known in the art and include, for example, the 













to glutamine or histidine; aspartate to glutamate; cysteine to 
serine; glutamine to asparagine; glutamate to aspartate; 
glycine to proline; histidine to asparagine or glutamine; 
isoleucine to leucine or valine; leucine to valine or isoleu 
cine; lysine to arginine; methionine to leucine or isoleucine; 
phenylalanine to tyrosine, leucine, or methionine; serine to 
threonine; threonine to serine; tryptophan to tyrosine; tyro 
sine to tryptophan or phenylalanine; and valine to isoleucine 
or leucine. 
In addition to a deletion or substitution, a modified protein 
may possess an insertion of residues, which typically 
involves the addition of at least one residue in the polypep 
tide. This may include the insertion of a targeting peptide or 
polypeptide or simply a single residue. Terminal additions, 
called fusion proteins, are discussed below. 
The term “biologically functional equivalent” is well 
understood in the art and is further defined in detail herein. 
Accordingly, sequences that have between about 70% and 
about 80%, or between about 81% and about 90%, or even 
between about 91% and about 99% of amino acids that are 
identical or functionally equivalent to the amino acids of a 
control polypeptide are included, provided the biological 
activity of the protein is maintained. A modified protein may 
be biologically functionally equivalent to its native coun 
terpart in certain aspects. 
It also will be understood that amino acid and nucleic acid 
sequences may include additional residues, such as addi 
tional N- or C-terminal amino acids or 5' or 3' sequences, 
and yet still be essentially as set forth in one of the sequences 
disclosed herein, so long as the sequence meets the criteria 
set forth above, including the maintenance of biological 
protein activity where protein expression is concerned. The 
addition of terminal sequences particularly applies to nucleic 
acid sequences that may, for example, include various 
non-coding sequences flanking either of the 5' or 3' portions 
of the coding region or may include various internal 
sequences, i.e., introns, which are known to occur within 
genes. 
IV. ENZYMATIC L-METHIONINE DEPLETION 
FOR THERAPY 
In certain aspects, the polypeptides may be used for the 
treatment of diseases, including cancers that are sensitive to 
methionine depletion, Such as hepatocellular carcinoma, 
melanoma, and renal cell carcinoma, with novel enzymes 
that deplete L-methionine. The invention specifically dis 
closes treatment methods using modified cystathionine-y- 
lyase with methionine degrading activity. As described 
below, as currently available methionine-y-lyases are typi 
cally bacterially-derived proteins, there remain several prob 
lems for their use in human therapy. Certain embodiments of 
the present invention provide novel enzymes with methio 
nine-y-lyase activity for increased therapeutic efficacy. 
Methionine (L-Met) depletion has long been studied as a 
potential treatment for cancer. While L-Met is an essential 
amino acid, many malignant human cell lines and tumors 
have been shown to have a relatively greater requirement for 
methionine (Halpern et al., 1974; Kreis and Goodenow, 
1978; Breillout et al., 1990; Kreis et al., 1980: Kreis, 1979). 
Methionine-dependent tumor cell lines present no or low 
levels of methionine synthase, the enzyme that normally 
recycles homocysteine back to L-Met (Halpern et al., 1974: 
Ashe et al., 1974). Most normal cells can grow on precur 
sors, such as homocysteine and homocystine, whereas many 
malignant cells must scavenge L-Met directly from their 
extracellular environment. Also, any rapidly growing neo 
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plasm can be adversely affected by the lack of essential 
building blocks necessary for growth. Methionine is par 
ticularly important as its depletion leads not only to dimin 
ished protein synthesis, but also dysregulated S-adenosyl 
methionine (SAM)-dependent methylation pathways, which 
are particularly important for gene regulation. 
The differences in methionine requirements between nor 
mal and cancer cells provide a therapeutic opportunity. 
Enzymatic methionine depletion has been explored in a 
number of animal model studies as well as Phase I clinical 
trials (Tan et al., 1997a; Tan et al., 1996a; Lishko et al., 
1993: Tan et al., 1996b; Yoshioka et al., 1998; Yang et al., 
2004a: Yang et al., 2004b; Tan et al., 1997b). 
Because humans lack a methionine hydrolyzing enzyme, 
bacterial L-methionine-y-lyases, MGL, from various 
sources have been evaluated for cancer therapy. Methionine 
y-lyase catalyzes the conversion of methionine to meth 
anethiol, alpha-ketobutyrate, and ammonia. Bacterial 
enzymes from various sources have been purified and tested 
as methionine depleting agents against cancer cell lines. The 
P. putida (pMGL) source was selected for therapeutic appli 
cations due to its high catalytic activity, low K , and 
relatively high k value (Esaki and Soda, 1987: Ito et al., 
1976), in comparison to other sources. Furthermore, the 
gene for pMGL has been cloned into E. coli and the protein 
was expressed at a high protein yield (Tan et al., 1997a; Hori 
et al., 1996). 
In vivo studies have been performed on animal models, as 
well as humans. Tan et al. (1997a) performed studies with 
human tumors Xenografted into nude mice and found that 
lung, colon, kidney, brain, prostate, and melanoma cancers 
were all sensitive to pMGL. Additionally, no toxicity was 
detected at effective doses, as was determined by an absence 
of weight loss in the animals. Half-life in these experiments 
was determined to be only 2 has measured from collected 
blood samples. Additionally, infusion of PLP is required in 
order to maintain MGL activity. In spite of the very short 
half-life, Tan et al. (1997a) reported inhibition of tumor 
growth in comparison to a saline control. 
Yang et al. (2004b) studied the pharmacokinetics, the 
pharmacodynamics in terms of methionine depletion, the 
antigenicity, and toxicity of MGL in a primate model. 
Dose-ranging studies were performed at 1000-4000 units/kg 
administered intravenously. The highest dose was able to 
reduce plasma methionine to an undetectable level (less than 
0.5uM) by 30 min after injection, with the methionine level 
remaining undetectable for 8 h. Pharmacokinetic analysis 
showed that pMGL was eliminated with a half-life of 2.5 h. 
An administration of that dose every 8 h/day for 2 weeks 
resulted in a steady-state depletion of plasma methionine to 
less than 2 M. Mild toxicity was observed through 
decreased food intake and slight weight loss. Unfortunately, 
re-challenge on day 28 resulted in anaphylactic shock and 
death in one animal indicating that pMGL is highly immu 
nogenic, which is a significant disadvantage for human 
therapy. Subsequent pretreatment with hydrocortisone pre 
vented the anaphylactic reaction, although Vomiting was 
frequently observed. Additional re-challenges were carried 
out at days 66, 86, and 116. Anti-rMGL antibodies were 
detected after the first challenge, and increased in concen 
tration for the duration of treatment. 
In response to these observed obstacles to therapeutic 
implementation of MGL, Yang et al. (2004b) studied the 
PEGylation of the enzyme and its effect on half-life and 
immunogenicity. The enzyme was coupled to methoxypoly 
ethylene glycol succinimidylglutarate (MEGC-PEG-5000). 













kg (90 mg/kg) was sufficient to reduce plasma methionine to 
<5 umol/L for 12 h. Pharmacokinetic analysis showed a 
36-fold improvement in the serum clearance half-life of the 
PEGylated enzyme, as compared to the unPEGylated 
enzyme. PEGylating also attenuated immunogenicity some 
what as only slight toxicities of decreased food intake and 
minor weight loss were observed. However, the activity 
half-life was not improved as L-Met levels were only kept 
below detection levels for 12 has opposed to 8 h for the 
unPEGylated enzyme. These results, though promising for 
the use of an L-Met depleting enzyme as an anti-neoplastic 
agent, are challenged by significant shortcomings of immu 
nogenicity and pharmacokinetics. 
Certain aspects of the present invention provide a modi 
fied cyStathionine-y-lyase with methionine degrading activ 
ity for treating diseases, such as tumors. Particularly, the 
modified polypeptide may have human polypeptide 
sequences and thus may prevent allergic reactions in human 
patients, allow repeated dosing, and increase the therapeutic 
efficacy. 
Tumors for which the present treatment methods are 
useful include any malignant cell type. Such as those found 
in a solid tumor or a hematological tumor. Exemplary Solid 
tumors can include, but are not limited to, a tumor of an 
organ selected from the group consisting of pancreas, colon, 
cecum, stomach, brain, head, neck, ovary, kidney, larynx, 
sarcoma, lung, bladder, melanoma, prostate, and breast. 
Exemplary hematological tumors include tumors of the bone 
marrow, T or B cell malignancies, leukemias, lymphomas, 
blastomas, myelomas, and the like. Further examples of 
cancers that may be treated using the methods provided 
herein include, but are not limited to, carcinoma, lymphoma, 
blastoma, sarcoma, leukemia, squamous cell cancer, lung 
cancer (including Small-cell lung cancer, non-Small cell lung 
cancer, adenocarcinoma of the lung, and squamous carci 
noma of the lung), cancer of the peritoneum, hepatocellular 
cancer, gastric or stomach cancer (including gastrointestinal 
cancer and gastrointestinal Stromal cancer), pancreatic can 
cer, glioblastoma, cervical cancer, ovarian cancer, liver 
cancer, bladder cancer, breast cancer, colon cancer, colorec 
tal cancer, endometrial or uterine carcinoma, salivary gland 
carcinoma, kidney or renal cancer, prostate cancer, Vulval 
cancer, thyroid cancer, various types of head and neck 
cancer, melanoma, Superficial spreading melanoma, lentigo 
malignant melanoma, acral lentiginous melanomas, nodular 
melanomas, as well as B-cell lymphoma (including low 
grade/follicular non-Hodgkin’s lymphoma (NHL); small 
lymphocytic (SL) NHL; intermediate grade/follicular NHL: 
intermediate grade diffuse NHL; high grade immunoblastic 
NHL: high grade lymphoblastic NHL; high grade small 
non-cleaved cell NHL: bulky disease NHL; mantle cell 
lymphoma; AIDS-related lymphoma; and Waldenstrom's 
macroglobulinemia), chronic lymphocytic leukemia (CLL), 
acute lymphoblastic leukemia (ALL), Hairy cell leukemia, 
multiple myeloma, acute myeloid leukemia (AML) and 
chronic myeloblastic leukemia. 
The cancer may specifically be of the following histo 
logical type, though it is not limited to these: neoplasm, 
malignant; carcinoma; carcinoma, undifferentiated; giant 
and spindle cell carcinoma; Small cell carcinoma; papillary 
carcinoma; squamous cell carcinoma: lymphoepithelial car 
cinoma, basal cell carcinoma; pilomatrix carcinoma; transi 
tional cell carcinoma; papillary transitional cell carcinoma; 
adenocarcinoma; gastrinoma, malignant; cholangiocarci 
noma; hepatocellular carcinoma; combined hepatocellular 
carcinoma and cholangiocarcinoma; trabecular adenocarci 
noma, adenoid cystic carcinoma; adenocarcinoma in 
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adenomatous polyp; adenocarcinoma, familial polyposis 
coli; Solid carcinoma; carcinoid tumor, malignant; bran 
chiolo-alveolar adenocarcinoma; papillary adenocarcinoma; 
chromophobe carcinoma, acidophil carcinoma; oxyphilic 
adenocarcinoma, basophil carcinoma; clear cell adenocar 
cinoma; granular cell carcinoma; follicular adenocarcinoma; 
papillary and follicular adenocarcinoma; nonencapsulating 
Sclerosing carcinoma, adrenal cortical carcinoma; endo 
metroid carcinoma; skin appendage carcinoma; apocrine 
adenocarcinoma; sebaceous adenocarcinoma; ceruminous 
adenocarcinoma; muco epidermoid carcinoma; cystadeno 
carcinoma; papillary cystadenocarcinoma; papillary serous 
cystadenocarcinoma; mucinous cystadenocarcinoma; muci 
nous adenocarcinoma; signet ring cell carcinoma; infiltrat 
ing duct carcinoma; medullary carcinoma; lobular carci 
noma; inflammatory carcinoma; paget’s disease, mammary: 
acinar cell carcinoma; adenosquamous carcinoma; adeno 
carcinoma W/squamous metaplasia; thymoma, malignant; 
ovarian stromal tumor, malignant; thecoma, malignant; 
granulosa cell tumor, malignant; androblastoma, malignant; 
Sertoli cell carcinoma; leydig cell tumor, malignant; lipid 
cell tumor, malignant, paraganglioma, malignant; extra 
mammary paraganglioma, malignant; pheochromocytoma; 
glomangiosarcoma; malignant melanoma, amelanotic mela 
noma; Superficial spreading melanoma; malignant mela 
noma in giant pigmented nevus; epithelioid cell melanoma; 
blue nevus, malignant; sarcoma; fibrosarcoma; fibrous his 
tiocytoma, malignant; myxosarcoma; liposarcoma; leiomyo 
sarcoma, rhabdomyosarcoma; embryonal rhabdomyosar 
coma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed 
tumor, malignant; mullerian mixed tumor; nephroblastoma; 
hepatoblastoma; carcinosarcoma; mesenchymoma, malig 
nant; brenner tumor, malignant; phyllodes tumor, malignant; 
synovial sarcoma; mesothelioma, malignant; dysgermi 
noma, embryonal carcinoma; teratoma, malignant; struma 
ovarii, malignant; choriocarcinoma; mesonephroma, malig 
nant; hemangiosarcoma; hemangioendothelioma, malig 
nant; kaposi's sarcoma; hemangiopericytoma, malignant; 
lymphangiosarcoma; osteosarcoma; juxtacortical osteosar 
coma; chondrosarcoma; chondroblastoma, malignant; mes 
enchymal chondrosarcoma; giant cell tumor of bone; 
ewing's sarcoma; odontogenic tumor, malignant; ameloblas 
tic odontosarcoma; ameloblastoma, malignant; ameloblastic 
fibrosarcoma; pinealoma, malignant; chordoma; glioma, 
malignant; ependymoma; astrocytoma; protoplasmic astro 
cytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; 
oligodendroglioma, oligodendroblastoma; primitive neu 
roectodermal; cerebellar sarcoma; ganglioneuroblastoma; 
neuroblastoma; retinoblastoma, olfactory neurogenic tumor; 
meningioma, malignant; neurofibrosarcoma; neurilem 
moma, malignant; granular cell tumor, malignant; malignant 
lymphoma; hodgkin’s disease; hodgkins; paragranuloma; 
malignant lymphoma, Small lymphocytic; malignant lym 
phoma, large cell, diffuse; malignant lymphoma, follicular, 
mycosis fungoides; other specified non-hodgkin’s lympho 
mas; malignant histiocytosis; multiple myeloma; mast cell 
sarcoma; immunoproliferative Small intestinal disease; leu 
kemia: lymphoid leukemia; plasma cell leukemia; erythro 
leukemia: lymphosarcoma cell leukemia; myeloid leukemia; 
basophilic leukemia; eosinophilic leukemia; monocytic leu 
kemia; mast cell leukemia; megakaryoblastic leukemia; 
myeloid sarcoma; and hairy cell leukemia. 
The engineered human methioninase derived from cysta 
thionase may be used herein as an antitumor agent in a 













cell, tumor tissue, or the circulation of a mammal with 
cancer, or for depletion of methionine where its depletion is 
considered desirable. 
Depletion can be conducted in vivo in the circulation of 
a mammal, in vitro in cases where methionine depletion in 
tissue culture or other biological mediums is desired, and in 
ex vivo procedures where biological fluids, cells, or tissues 
are manipulated outside the body and Subsequently returned 
to the body of the patient mammal. Depletion of methionine 
from circulation, culture media, biological fluids, or cells is 
conducted to reduce the amount of methionine accessible to 
the material being treated, and therefore comprises contact 
ing the material to be depleted with a methionine-depleting 
amount of the engineered human methioninase under 
methionine-depleting conditions as to degrade the ambient 
methionine in the material being contacted. 
Because tumor cells are dependent upon their nutrient 
medium for methionine, the depletion may be directed to the 
nutrient source for the cells, and not necessarily the cells 
themselves. Therefore, in an in vivo application, treating a 
tumor cell includes contacting the nutrient medium for a 
population of tumor cells with the engineered methioninase. 
In this embodiment, the medium may be blood, lymphatic 
fluid, spinal fluid and the like bodily fluid where methionine 
depletion is desired. 
A methionine-depleting efficiency can vary widely 
depending upon the application, and typically depends upon 
the amount of methionine present in the material, the desired 
rate of depletion, and the tolerance of the material for 
exposure to methioninase. Methionine levels in a material, 
and therefore rates of methionine depletion from the mate 
rial, can readily be monitored by a variety of chemical and 
biochemical methods well known in the art. Exemplary 
methionine-depleting amounts are described further herein, 
and can range from 0.001 to 100 units (U) of engineered 
methioninase, preferably about 0.01 to 10 U, and more 
preferably about 0.1 to 5 U engineered methioninase per 
milliliter (mL) of material to be treated. 
Methionine-depleting conditions are buffer and tempera 
ture conditions compatible with the biological activity of a 
methioninase enzyme, and include moderate temperature, 
salt, and pH conditions compatible with the enzyme, for 
example, physiological conditions. Exemplary conditions 
include about 4-40° C., ionic strength equivalent to about 
0.05 to 0.2 M NaCl, and a pH of about 5 to 9, while 
physiological conditions are included. 
In a particular embodiment, the invention contemplates 
methods of using engineered methioninase as an antitumor 
agent, and therefore comprises contacting a population of 
tumor cells with a therapeutically effective amount of engi 
neered methioninase for a time period sufficient to inhibit 
tumor cell growth. 
In one embodiment, the contacting in Vivo is accom 
plished by administering, by intravenous or intraperitoneal 
injection, a therapeutically effective amount of a physiologi 
cally tolerable composition comprising an engineered 
methioninase of this invention to a patient, thereby depleting 
the circulating methionine source of the tumor cells present 
in the patient. The contacting of engineered methioninase 
can also be accomplished by administering the engineered 
methioninase into the tissue containing the tumor cells. 
A therapeutically effective amount of an engineered 
methioninase is a predetermined amount calculated to 
achieve the desired effect, i.e., to deplete methionine in the 
tumor tissue or in a patients circulation, and thereby cause 
the tumor cells to stop dividing. Thus, the dosage ranges for 
the administration of engineered methioninase of the inven 
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tion are those large enough to produce the desired effect in 
which the symptoms of tumor cell division and cell cycling 
are reduced. The dosage should not be so large as to cause 
adverse side effects, such as hyperviscosity syndromes, 
pulmonary edema, congestive heart failure, and the like. 
Generally, the dosage will vary with age of condition of sex 
of and extent of the disease in the patient and can be 
determined by one of skill in the art. The dosage can be 
adjusted by the individual physician in the event of any 
complication. 
For example, a therapeutically effective amount of an 
engineered methioninase may be an amount Such that when 
administered in a physiologically tolerable composition is 
Sufficient to achieve an intravascular (plasma) or local 
concentration of from about 0.001 to about 100 units (U) per 
mL, preferably above about 0.1 U, and more preferably 
above 1 U engineered methioninase per mL. Typical dosages 
can be administered based on body weight, and are in the 
range of about 5-1000 U/kilogram (kg)/day, preferably 
about 5-100 U/kg/day, more preferably about 10-50 U/kg/ 
day, and more preferably about 20-40 U/kg/day. 
The engineered methioninase can be administered paren 
terally by injection or by gradual infusion over time. The 
engineered methioninase can be administered intravenously, 
intraperitoneally, orally, intramuscularly, Subcutaneously, 
intracavity, transdermally, dermally, can be delivered by 
peristaltic means, can be injected directly into the tissue 
containing the tumor cells, or can be administered by a pump 
connected to a catheter that may contain a potential biosen 
sor or methionine. 
The therapeutic compositions containing engineered 
methioninase are conventionally administered intrave 
nously, as by injection of a unit dose, for example. The term 
“unit dose' when used in reference to a therapeutic compo 
sition refers to physically discrete units Suitable as unitary 
dosage for the Subject, each unit containing a predetermined 
quantity of active material calculated to produce the desired 
therapeutic effect in association with the required diluent, 
i.e., carrier, or vehicle. 
The compositions are administered in a manner compat 
ible with the dosage formulation, and in a therapeutically 
effective amount. The quantity to be administered depends 
on the Subject to be treated, capacity of the Subject's system 
to utilize the active ingredient, and degree of therapeutic 
effect desired. Precise amounts of active ingredient required 
to be administered depend on the judgment of the practitio 
ner and are peculiar to each individual. However, suitable 
dosage ranges for systemic application are disclosed herein 
and depend on the route of administration. Suitable regimes 
for initial administration and booster shots are also contem 
plated and are typified by an initial administration followed 
by repeated doses at one or more hour intervals by a 
Subsequent injection or other administration. Exemplary 
multiple administrations are described herein and are par 
ticularly preferred to maintain continuously high serum and 
tissue levels of engineered methioninase and conversely low 
serum and tissue levels of methionine. Alternatively, con 
tinuous intravenous infusion Sufficient to maintain concen 
trations in the blood in the ranges specified for in vivo 
therapies are contemplated. 
V. CONJUGATES 
Compositions and methods of the present invention 
involve further modification of the engineered methioninase 
for improvement, such as by forming conjugates with het 













ylene glycol. In further aspects, the engineered methioninase 
may be linked to PEG to increase the hydrodynamic radius 
of the enzyme and hence increase the serum persistence. In 
certain aspects, the disclosed polypeptide may be conjugated 
to any targeting agent, such as a ligand having the ability to 
specifically and stably bind to an external receptor or 
binding site on a tumor cell (U.S. Patent Publ. 2009/ 
0304666). 
A. Fusion Proteins 
Certain embodiments of the present invention concern 
fusion proteins. These molecules may have the engineered 
human methioninase linked at the N- or C-terminus to a 
heterologous domain. For example, fusions may also 
employ leader sequences from other species to permit the 
recombinant expression of a protein in a heterologous host. 
Another useful fusion includes the addition of a protein 
affinity tag. Such as a serum albumin affinity tag or six 
histidine residues, or an immunologically active domain, 
Such as an antibody epitope, preferably cleavable, to facili 
tate purification of the fusion protein. Non-limiting affinity 
tags include polyhistidine, chitin binding protein (CBP), 
maltose binding protein (MBP), and glutathione-S-trans 
ferase (GST). 
In a particular embodiment, the engineered human 
methioninase may be linked to a peptide that increases the 
in vivo half-life, such as an XTEN polypeptide (Schellen 
berger et al., 2009), IgGFc domain, albumin, or an albumin 
binding peptide. 
Methods of generating fusion proteins are well known to 
those of skill in the art. Such proteins can be produced, for 
example, by de novo synthesis of the complete fusion 
protein, or by attachment of the DNA sequence encoding the 
heterologous domain, followed by expression of the intact 
fusion protein. 
Production of fusion proteins that recover the functional 
activities of the parent proteins may be facilitated by con 
necting genes with a bridging DNA segment encoding a 
peptide linker that is spliced between the polypeptides 
connected in tandem. The linker would be of sufficient 
length to allow proper folding of the resulting fusion protein. 
B. Linkers 
In certain embodiments, the engineered methioninase 
may be chemically conjugated using bifunctional cross 
linking reagents or fused at the protein level with peptide 
linkers. 
Bifunctional cross-linking reagents have been extensively 
used for a variety of purposes, including preparation of 
affinity matrices, modification and stabilization of diverse 
structures, identification of ligand and receptor binding sites, 
and structural studies. Suitable peptide linkers may also be 
used to link the engineered methioninase, Such as Gly-Ser 
linkers. 
Homobifunctional reagents that carry two identical func 
tional groups proved to be highly efficient in inducing 
cross-linking between identical and different macromol 
ecules or subunits of a macromolecule, and linking of 
polypeptide ligands to their specific binding sites. Hetero 
bifunctional reagents contain two different functional 
groups. By taking advantage of the differential reactivities of 
the two different functional groups, cross-linking can be 
controlled both selectively and sequentially. The bifunc 
tional cross-linking reagents can be divided according to the 
specificity of their functional groups, e.g., amino-, sulfhy 
dryl-, guanidine-, indole-, carboxyl-specific groups. Of 
these, reagents directed to free amino groups have become 
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especially popular because of their commercial availability, 
ease of synthesis, and the mild reaction conditions under 
which they can be applied. 
A majority of heterobifunctional cross-linking reagents 
contain a primary amine-reactive group and a thiol-reactive 5 
group. In another example, heterobifunctional cross-linking 
reagents and methods of using the cross-linking reagents are 
described (U.S. Pat. No. 5,889,155, specifically incorporated 
herein by reference in its entirety). The cross-linking 
reagents combine a nucleophilic hydrazide residue with an 
electrophilic maleimide residue, allowing coupling, in one 
example, of aldehydes to free thiols. The cross-linking 
reagent can be modified to cross-link various functional 
groups. 
Additionally, any other linking/coupling agents and/or 
mechanisms known to those of skill in the art may be used 
to combine human engineered methioninase, such as, for 
example, antibody-antigen interaction, avidin biotin link 
ages, amide linkages, ester linkages, thioester linkages, ether 
linkages, thioether linkages, phosphoester linkages, phos 
phoramide linkages, anhydride linkages, disulfide linkages, 
ionic and hydrophobic interactions, bispecific antibodies and 
antibody fragments, or combinations thereof. 
It is preferred that a cross-linker having reasonable sta 
bility in blood will be employed. Numerous types of disul 
fide-bond containing linkers are known that can be success 
fully employed to conjugate targeting and therapeutic/ 
preventative agents. Linkers that contain a disulfide bond 
that is sterically hindered may prove to give greater stability 
in vivo. These linkers are thus one group of linking agents. 
In addition to hindered cross-linkers, non-hindered linkers 
also can be employed in accordance herewith. Other useful 
cross-linkers, not considered to contain or generate a pro 
tected disulfide, include SATA, SPDP, and 2-iminothiolane 
(Wawrzynczak and Thorpe, 1987). The use of such cross 
linkers is well understood in the art. Another embodiment 
involves the use of flexible linkers. 
Once chemically conjugated, the peptide generally will be 
purified to separate the conjugate from unconjugated agents 
and from other contaminants. A large number of purification 
techniques are available for use in providing conjugates of 
a sufficient degree of purity to render them clinically useful. 
Purification methods based upon size separation, such as 
gel filtration, gel permeation, or high performance liquid 
chromatography, will generally be of most use. Other chro- 45 
matographic techniques, such as Blue-Sepharose separation, 
may also be used. Conventional methods to purify the fusion 
proteins from inclusion bodies may be useful, Such as using 
weak detergents, such as Sodium N-lauroyl-sarcosine (SLS). 
C. PEGylation 
In certain aspects of the invention, methods and compo 
sitions related to PEGylation of engineered methioninase are 
disclosed. For example, the engineered methioninase may be 
PEGylated in accordance with the methods disclosed herein. 
PEGylation is the process of covalent attachment of 55 
poly(ethylene glycol) polymer chains to another molecule, 
normally a drug or therapeutic protein. PEGylation is rou 
tinely achieved by incubation of a reactive derivative of 
PEG with the target macromolecule. The covalent attach 
ment of PEG to a drug or therapeutic protein can “mask' the 60 
agent from the host’s immune system (reduced immunoge 
nicity and antigenicity) or increase the hydrodynamic size 
(size in Solution) of the agent, which prolongs its circulatory 
time by reducing renal clearance. PEGylation can also 
provide water solubility to hydrophobic drugs and proteins. 65 
The first step of the PEGylation is the suitable function 









that are activated at each terminus with the same reactive 
moiety are known as “homobifunctional,” whereas if the 
functional groups present are different, then the PEG deriva 
tive is referred as "heterobifunctional' or "heterofunc 
tional.” The chemically active or activated derivatives of the 
PEG polymer are prepared to attach the PEG to the desired 
molecule. 
The choice of the suitable functional group for the PEG 
derivative is based on the type of available reactive group on 
the molecule that will be coupled to the PEG. For proteins, 
typical reactive amino acids include lysine, cysteine, histi 
dine, arginine, aspartic acid, glutamic acid, serine, threonine, 
and tyrosine. The N-terminal amino group and the C-termi 
nal carboxylic acid can also be used. 
The techniques used to form first generation PEG deriva 
tives are generally reacting the PEG polymer with a group 
that is reactive with hydroxyl groups, typically anhydrides, 
acid chlorides, chloroformates, and carbonates. In the sec 
ond generation PEGylation chemistry more efficient func 
tional groups, such as aldehyde, esters, amides, etc., are 
made available for conjugation. 
As applications of PEGylation have become more and 
more advanced and Sophisticated, there has been an increase 
in need for heterobifunctional PEGs for conjugation. These 
heterobifunctional PEGs are very useful in linking two 
entities, where a hydrophilic, flexible, and biocompatible 
spacer is needed. Preferred end groups for heterobifunc 
tional PEGs are maleimide, vinyl sulfones, pyridyl disulfide, 
amine, carboxylic acids, and NHS esters. 
The most common modification agents, or linkers, are 
based on methoxy PEG (mPEG) molecules. Their activity 
depends on adding a protein-modifying group to the alcohol 
end. In some instances polyethylene glycol (PEG diol) is 
used as the precursor molecule. The diol is Subsequently 
modified at both ends in order to make a hetero- or homo 
dimeric PEG-linked molecule. 
Proteins are generally PEGylated at nucleophilic sites, 
Such as unprotonated thiols (cysteinyl residues) or amino 
groups. Examples of cysteinyl-specific modification 
reagents include PEG maleimide, PEG iodoacetate, PEG 
thiols, and PEG vinylsulfone. All four are strongly cysteinyl 
specific under mild conditions and neutral to slightly alka 
line pH but each has some drawbacks. The thioether formed 
with the maleimides can be somewhat unstable under alka 
line conditions so there may be some limitation to formu 
lation options with this linker. The carbamothioate linkage 
formed with iodo PEGs is more stable, but free iodine can 
modify tyrosine residues under some conditions. PEG thiols 
form disulfide bonds with protein thiols, but this linkage can 
also be unstable under alkaline conditions. PEG-vinylsul 
fone reactivity is relatively slow compared to maleimide and 
iodo PEG; however, the thioether linkage formed is quite 
stable. Its slower reaction rate also can make the PEG 
vinylsulfone reaction easier to control. 
Site-specific PEGylation at native cysteinyl residues is 
seldom carried out, since these residues are usually in the 
form of disulfide bonds or are required for biological activ 
ity. On the other hand, site-directed mutagenesis can be used 
to incorporate cysteinyl PEGylation sites for thiol-specific 
linkers. The cysteine mutation must be designed such that it 
is accessible to the PEGylation reagent and is still biologi 
cally active after PEGylation. 
Amine-specific modification agents include PEG NHS 
ester, PEG tresylate, PEG aldehyde, PEG isothiocyanate, 
and several others. All react under mild conditions and are 
very specific for amino groups. The PEG NHS ester is 
probably one of the more reactive agents; however, its high 
US 9,481,877 B2 
21 
reactivity can make the PEGylation reaction difficult to 
control on a large scale. PEG aldehyde forms an imine with 
the amino group, which is then reduced to a secondary 
amine with sodium cyanoborohydride. Unlike sodium boro 
hydride, sodium cyanoborohydride will not reduce disulfide 
bonds. However, this chemical is highly toxic and must be 
handled cautiously, particularly at lower pH where it 
becomes volatile. 
Due to the multiple lysine residues on most proteins, 
site-specific PEGylation can be a challenge. Fortunately, 
because these reagents react with unprotonated amino 
groups, it is possible to direct the PEGylation to lower-pK 
amino groups by performing the reaction at a lower pH. 
Generally the pK of the alpha-amino group is 1-2 pH units 
lower than the epsilon-amino group of lysine residues. By 
PEGylating the molecule at pH 7 or below, high selectivity 
for the N-terminus frequently can be attained. However, this 
is only feasible if the N-terminal portion of the protein is not 
required for biological activity. Still, the pharmacokinetic 
benefits from PEGylation frequently outweigh a significant 
loss of in vitro bioactivity, resulting in a product with much 
greater in vivo bioactivity regardless of PEGylation chem 
istry. 
There are several parameters to consider when developing 
a PEGylation procedure. Fortunately, there are usually no 
more than four or five key parameters. The “design of 
experiments' approach to optimization of PEGylation con 
ditions can be very useful. For thiol-specific PEGylation 
reactions, parameters to consider include: protein concen 
tration, PEG-to-protein ratio (on a molar basis), temperature, 
pH, reaction time, and in some instances, the exclusion of 
oxygen. (Oxygen can contribute to intermolecular disulfide 
formation by the protein, which will reduce the yield of the 
PEGylated product.) The same factors should be considered 
(with the exception of oxygen) for amine-specific modifi 
cation except that pH may be even more critical, particularly 
when targeting the N-terminal amino group. 
For both amine- and thiol-specific modifications, the 
reaction conditions may affect the stability of the protein. 
This may limit the temperature, protein concentration, and 
pH. In addition, the reactivity of the PEG linker should be 
known before starting the PEGylation reaction. For 
example, if the PEGylation agent is only 70% active, the 
amount of PEG used should ensure that only active PEG 
molecules are counted in the protein-to-PEG reaction stoi 
chiometry. 
VI. PROTEINS AND PEPTIDES 
In certain embodiments, the present invention concerns 
novel compositions comprising at least one protein or pep 
tide. Such as an engineered methioninase. These peptides 
may be comprised in a fusion protein or conjugated to an 
agent as described Supra. 
As used herein, a protein or peptide generally refers, but 
is not limited to, a protein of greater than about 200 amino 
acids, up to a full-length sequence translated from a gene; a 
polypeptide of greater than about 100 amino acids; and/or a 
peptide of from about 3 to about 100 amino acids. For 
convenience, the terms “protein.” “polypeptide,” and "pep 
tide' are used interchangeably herein. 
As used herein, an "amino acid residue' refers to any 
naturally occurring amino acid, any amino acid derivative, 
or any amino acid mimic known in the art. In certain 
embodiments, the residues of the protein or peptide are 
sequential, without any non-amino acids interrupting the 













sequence may comprise one or more non-amino acid moi 
eties. In particular embodiments, the sequence of residues of 
the protein or peptide may be interrupted by one or more 
non-amino acid moieties. 
Accordingly, the term “protein or peptide' encompasses 
amino acid sequences comprising at least one of the 20 
common amino acids found in naturally occurring proteins, 
or at least one modified or unusual amino acid. 
Proteins or peptides may be made by any technique 
known to those of skill in the art, including the expression 
of proteins, polypeptides, or peptides through standard 
molecular biological techniques, the isolation of proteins or 
peptides from natural Sources, or the chemical synthesis of 
proteins or peptides. The nucleotide and protein, polypep 
tide, and peptide sequences corresponding to various genes 
have been previously disclosed, and may be found at com 
puterized databases known to those of ordinary skill in the 
art. One such database is the National Center for Biotech 
nology Informations Genbank and GenPept databases 
(available on the world wide web at ncbi.nlm.nih.gov/). The 
coding regions for known genes may be amplified and/or 
expressed using the techniques disclosed herein or as would 
be known to those of ordinary skill in the art. Alternatively, 
various commercial preparations of proteins, polypeptides, 
and peptides are known to those of skill in the art. 
VII. NUCLEIC ACIDS AND VECTORS 
In certain aspects of the invention, nucleic acid sequences 
encoding an engineered methioninase or a fusion protein 
containing an engineered human methioninase may be dis 
closed. Depending on which expression system is used, 
nucleic acid sequences can be selected based on conven 
tional methods. For example, if the engineered methioninase 
is derived from human cystathionase and contains multiple 
codons that are rarely utilized in E. coli, then that may 
interfere with expression. Therefore, the respective genes or 
variants thereof may be codon optimized for E. coli expres 
Sion. Various vectors may be also used to express the protein 
of interest, such as engineered methioninase. Exemplary 
vectors include, but are not limited, plasmid vectors, viral 
vectors, transposon, or liposome-based vectors. 
VIII. HOST CELLS 
Host cells may be any that may be transformed to allow 
the expression and secretion of engineered methioninase and 
conjugates thereof. The host cells may be bacteria, mam 
malian cells, yeast, or filamentous fungi. Various bacteria 
include Escherichia and Bacillus. Yeasts belonging to the 
genera Saccharomyces, Kiuyveromyces, Hansenula, or 
Pichia would find use as an appropriate host cell. Various 
species of filamentous fungi may be used as expression 
hosts, including the following genera: Aspergillus, 
Trichoderma, Neurospora, Penicillium, Cephalosporium, 
Achlya, Podospora, Endothia, Mucor, Cochliobolus, and 
Pyricularia. 
Examples of usable host organisms include bacteria, e.g., 
Escherichia coli MC1061, derivatives of Bacillus subtilis 
BRB1 (Sibakov et al., 1984), Staphylococcus aureus 
SAI123 (Lordanescu, 1975) or Streptococcus lividans (Hop 
wood et al., 1985); yeasts, e.g., Saccharomyces cerevisiae 
AH 22 (Mellor et al., 1983) or Schizosaccharomyces pombe: 
and filamentous fungi, e.g., Aspergillus nidulans, Aspergil 
lus awamori (Ward, 1989), or Trichoderma reesei (Penttila 
et al., 1987; Harkki et al., 1989). 
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Examples of mammalian host cells include Chinese ham 
ster ovary cells (CHO-K1; ATCCCCL61), rat pituitary cells 
(GH1; ATCC CCL82), HeLa S3 cells (ATCC CCL2.2), rat 
hepatoma cells (H-4-II-E; ATCCCRL 1548), SV40-trans 
formed monkey kidney cells (COS-1; ATCC CRL 1650), 
and murine embryonic cells (NIH-3T3: ATCC CRL 1658). 
The foregoing is meant to be illustrative but not limitative of 
the many possible host organisms known in the art. In 
principle, all hosts capable of secretion can be used whether 
prokaryotic or eukaryotic. 
Mammalian host cells expressing the engineered methio 
ninases and/or their fusion proteins are cultured under 
conditions typically employed to culture the parental cell 
line. Generally, cells are cultured in a standard medium 
containing physiological salts and nutrients, such as stan 
dard RPMI, MEM, IMEM, or DMEM, typically supple 
mented with 5%-10% serum, such as fetal bovine serum. 
Culture conditions are also standard, e.g., cultures are incu 
bated at 37° C. in stationary or roller cultures until desired 
levels of the proteins are achieved. 
IX PROTEIN PURIFICATION 
Protein purification techniques are well known to those of 
skill in the art. These techniques involve, at one level, the 
homogenization and crude fractionation of the cells, tissue, 
or organ to polypeptide and non-polypeptide fractions. The 
protein or polypeptide of interest may be further purified 
using chromatographic and electrophoretic techniques to 
achieve partial or complete purification (or purification to 
homogeneity) unless otherwise specified. Analytical meth 
ods particularly suited to the preparation of a pure peptide 
are ion-exchange chromatography, gel exclusion chroma 
tography, polyacrylamide gel electrophoresis, affinity chro 
matography, immunoaffinity chromatography, and isoelec 
tric focusing. A particularly efficient method of purifying 
peptides is fast-performance liquid chromatography (FPLC) 
or even high-performance liquid chromatography (HPLC). 
A purified protein or peptide is intended to refer to a 
composition, isolatable from other components, wherein the 
protein or peptide is purified to any degree relative to its 
naturally-obtainable state. An isolated or purified protein or 
peptide, therefore, also refers to a protein or peptide free 
from the environment in which it may naturally occur. 
Generally, “purified will refer to a protein or peptide 
composition that has been subjected to fractionation to 
remove various other components, and which composition 
substantially retains its expressed biological activity. Where 
the term “substantially purified' is used, this designation 
will refer to a composition in which the protein or peptide 
forms the major component of the composition, such as 
constituting about 50%, about 60%, about 70%, about 80%, 
about 90%, about 95%, or more of the proteins in the 
composition. 
Various techniques Suitable for use in protein purification 
are well known to those of skill in the art. These include, for 
example, precipitation with ammonium Sulfate, PEG, anti 
bodies and the like, or by heat denaturation, followed by 
centrifugation; chromatography steps, such as ion exchange, 
gel filtration, reverse phase, hydroxyapatite, and affinity 
chromatography; isoelectric focusing; gel electrophoresis; 
and combinations of these and other techniques. As is 
generally known in the art, it is believed that the order of 
conducting the various purification steps may be changed, or 
that certain steps may be omitted, and still result in a Suitable 














Various methods for quantifying the degree of purification 
of the protein or peptide are known to those of skill in the 
art in light of the present disclosure. These include, for 
example, determining the specific activity of an active 
fraction, or assessing the amount of polypeptides within a 
fraction by SDS/PAGE analysis. A preferred method for 
assessing the purity of a fraction is to calculate the specific 
activity of the fraction, to compare it to the specific activity 
of the initial extract, and to thus calculate the degree of 
purity therein, assessed by a “-fold purification number.” 
The actual units used to represent the amount of activity 
will, of course, be dependent upon the particular assay 
technique chosen to follow the purification, and whether or 
not the expressed protein or peptide exhibits a detectable 
activity. 
There is no general requirement that the protein or peptide 
will always be provided in its most purified state. Indeed, it 
is contemplated that less Substantially purified products may 
have utility in certain embodiments. Partial purification may 
be accomplished by using fewer purification steps in com 
bination, or by utilizing different forms of the same general 
purification scheme. For example, it is appreciated that a 
cation-exchange column chromatography performed utiliz 
ing an HPLC apparatus will generally result in a greater 
“-fold' purification than the same technique utilizing a low 
pressure chromatography system. Methods exhibiting a 
lower degree of relative purification may have advantages in 
total recovery of protein product, or in maintaining the 
activity of an expressed protein. 
In certain embodiments a protein or peptide may be 
isolated or purified, for example, an engineered methioni 
nase, a fusion protein containing the engineered methioni 
nase, or an engineered methioninase post PEGylation. For 
example, a His tag or an affinity epitope may be comprised 
in Such an engineered methioninase to facilitate purification. 
Affinity chromatography is a chromatographic procedure 
that relies on the specific affinity between a substance to be 
isolated and a molecule to which it can specifically bind. 
This is a receptor-ligand type of interaction. The column 
material is synthesized by covalently coupling one of the 
binding partners to an insoluble matrix. The column material 
is then able to specifically adsorb the substance from the 
Solution. Elution occurs by changing the conditions to those 
in which binding will not occur (e.g., altered pH, ionic 
strength, temperature, etc.). The matrix should be a Sub 
stance that does not adsorb molecules to any significant 
extent and that has a broad range of chemical, physical, and 
thermal stability. The ligand should be coupled in such a way 
as to not affect its binding properties. The ligand should also 
provide relatively tight binding. It should be possible to elute 
the Substance without destroying the sample or the ligand. 
Size exclusion chromatography (SEC) is a chromato 
graphic method in which molecules in Solution are separated 
based on their size, or in more technical terms, their hydro 
dynamic Volume. It is usually applied to large molecules or 
macromolecular complexes, such as proteins and industrial 
polymers. Typically, when an aqueous Solution is used to 
transport the sample through the column, the technique is 
known as gel filtration chromatography, versus the name gel 
permeation chromatography, which is used when an organic 
Solvent is used as a mobile phase. 
The underlying principle of SEC is that particles of 
different sizes will elute (filter) through a stationary phase at 
different rates. This results in the separation of a solution of 
particles based on size. Provided that all the particles are 
loaded simultaneously or near simultaneously, particles of 
the same size should elute together. Each size exclusion 
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column has a range of molecular weights that can be 
separated. The exclusion limit defines the molecular weight 
at the upper end of this range and is where molecules are too 
large to be trapped in the stationary phase. The permeation 
limit defines the molecular weight at the lower end of the 
range of separation and is where molecules of a small 
enough size can penetrate into the pores of the stationary 
phase completely and all molecules below this molecular 
mass are so Small that they elute as a single band. 
High-performance liquid chromatography (or high-pres 
Sure liquid chromatography, HPLC) is a form of column 
chromatography used frequently in biochemistry and ana 
lytical chemistry to separate, identify, and quantify com 
pounds. HPLC utilizes a column that holds chromatographic 
packing material (stationary phase), a pump that moves the 
mobile phase(s) through the column, and a detector that 
shows the retention times of the molecules. Retention time 
varies depending on the interactions between the stationary 
phase, the molecules being analyzed, and the Solvent(s) 
used. 
X. PHARMACEUTICAL COMPOSITIONS 
It is contemplated that the novel methioninase can be 
administered systemically or locally to inhibit tumor cell 
growth and, most preferably, to kill cancer cells in cancer 
patients with locally advanced or metastatic cancers. They 
can be administered intravenously, intrathecally, and/or 
intraperitoneally. They can be administered alone or in 
combination with anti-proliferative drugs. In one embodi 
ment, they are administered to reduce the cancer load in the 
patient prior to surgery or other procedures. Alternatively, 
they can be administered after Surgery to ensure that any 
remaining cancer (e.g., cancer that the Surgery failed to 
eliminate) does not survive. 
It is not intended that the present invention be limited by 
the particular nature of the therapeutic preparation. For 
example, Such compositions can be provided in formulations 
together with physiologically tolerable liquid, gel, or Solid 
carriers, diluents, and excipients. These therapeutic prepa 
rations can be administered to mammals for veterinary use, 
Such as with domestic animals, and clinical use in humans 
in a manner similar to other therapeutic agents. In general, 
the dosage required for therapeutic efficacy will vary accord 
ing to the type of use and mode of administration, as well as 
the particularized requirements of individual Subjects. 
Such compositions are typically prepared as liquid solu 
tions or Suspensions, for use as injectables. Suitable diluents 
and excipients are, for example, water, saline, dextrose, 
glycerol, or the like, and combinations thereof. In addition, 
if desired, the compositions may contain minor amounts of 
auxiliary Substances, such as wetting or emulsifying agents, 
stabilizing agents, or pH buffering agents. 
Where clinical applications are contemplated, it may be 
necessary to prepare pharmaceutical compositions compris 
ing proteins, antibodies, and drugs in a form appropriate for 
the intended application. Generally, pharmaceutical compo 
sitions may comprise an effective amount of one or more 
engineered methioninase or additional agents dissolved or 
dispersed in a pharmaceutically acceptable carrier. The 
phrases “pharmaceutical or pharmacologically acceptable' 
refers to molecular entities and compositions that do not 
produce an adverse, allergic, or other untoward reaction 
when administered to an animal. Such as, for example, a 
human, as appropriate. The preparation of a pharmaceutical 
composition that contains at least one engineered methio 














active ingredient will be known to those of skill in the art in 
light of the present disclosure, as exemplified by Reming 
ton's Pharmaceutical Sciences, 18th Ed., 1990, incorporated 
herein by reference. Moreover, for animal (e.g., human) 
administration, it will be understood that preparations 
should meet sterility, pyrogenicity, general safety, and purity 
standards as required by the FDA Office of Biological 
Standards. 
As used herein, “pharmaceutically acceptable carrier' 
includes any and all solvents, dispersion media, coatings, 
Surfactants, antioxidants, preservatives (e.g., antibacterial 
agents, antifungal agents), isotonic agents, absorption delay 
ing agents, salts, preservatives, drugs, drug stabilizers, gels, 
binders, excipients, disintegration agents, lubricants, Sweet 
ening agents, flavoring agents, dyes, such like materials and 
combinations thereof, as would be known to one of ordinary 
skill in the art (see, for example, Remington’s Pharmaceu 
tical Sciences, 18th Ed., 1990, incorporated herein by ref 
erence). Except insofar as any conventional carrier is incom 
patible with the active ingredient, its use in the 
pharmaceutical compositions is contemplated. 
Certain embodiments of the present invention may com 
prise different types of carriers depending on whether it is to 
be administered in Solid, liquid, or aerosol form, and 
whether it needs to be sterile for the route of administration, 
Such as injection. The compositions can be administered 
intravenously, intradermally, transdermally, intrathecally, 
intraarterially, intraperitoneally, intranasally, intravaginally, 
intrarectally, intramuscularly, Subcutaneously, mucosally, 
orally, topically, locally, by inhalation (e.g., aerosol inhala 
tion), by injection, by infusion, by continuous infusion, by 
localized perfusion bathing target cells directly, via a cath 
eter, via a lavage, in lipid compositions (e.g., liposomes), or 
by other methods or any combination of the forgoing as 
would be known to one of ordinary skill in the art (see, for 
example, Remington’s Pharmaceutical Sciences, 18th Ed., 
1990, incorporated herein by reference). 
The modified polypeptides may be formulated into a 
composition in a free base, neutral, or salt form. Pharma 
ceutically acceptable salts include the acid addition salts, 
e.g., those formed with the free amino groups of a proteina 
ceous composition, or which are formed with inorganic 
acids, such as, for example, hydrochloric or phosphoric 
acids, or Such organic acids as acetic, oxalic, tartaric, or 
mandelic acid. Salts formed with the free carboxyl groups 
can also be derived from inorganic bases, such as, for 
example, sodium, potassium, ammonium, calcium, or ferric 
hydroxides; or Such organic bases as isopropylamine, trim 
ethylamine, histidine, or procaine. Upon formulation, Solu 
tions will be administered in a manner compatible with the 
dosage formulation and in Such amount as is therapeutically 
effective. The formulations are easily administered in a 
variety of dosage forms, such as formulated for parenteral 
administrations, such as injectable solutions, or aerosols for 
delivery to the lungs, or formulated for alimentary admin 
istrations, such as drug release capsules and the like. 
Further in accordance with certain aspects of the present 
invention, the composition Suitable for administration may 
be provided in a pharmaceutically acceptable carrier with or 
without an inert diluent. The carrier should be assimilable 
and includes liquid, semi-solid, i.e., pastes, or solid carriers. 
Except insofar as any conventional media, agent, diluent, or 
carrier is detrimental to the recipient or to the therapeutic 
effectiveness of the composition contained therein, its use in 
administrable composition for use in practicing the methods 
is appropriate. Examples of carriers or diluents include fats, 
oils, water, saline solutions, lipids, liposomes, resins, bind 
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ers, fillers, and the like, or combinations thereof. The com 
position may also comprise various antioxidants to retard 
oxidation of one or more component. Additionally, the 
prevention of the action of microorganisms can be brought 
about by preservatives. Such as various antibacterial and 5 
antifungal agents, including but not limited to parabens (e.g., 
methylparabens, propylparabens), chlorobutanol, phenol, 
sorbic acid, thimerosal or combinations thereof. 
In accordance with certain aspects of the present inven 
tion, the composition is combined with the carrier in any 10 
convenient and practical manner, i.e., by Solution, Suspen 
Sion, emulsification, admixture, encapsulation, absorption, 
and the like. Such procedures are routine for those skilled in 
the art. 
In a specific embodiment of the present invention, the 15 
composition is combined or mixed thoroughly with a semi 
Solid or Solid carrier. The mixing can be carried out in any 
convenient manner. Such as grinding. Stabilizing agents can 
be also added in the mixing process in order to protect the 
composition from loss of therapeutic activity, i.e., denatur- 20 
ation in the stomach. Examples of Stabilizers for use in a 
composition include buffers, amino acids, such as glycine 
and lysine, carbohydrates, such as dextrose, mannose, galac 
tose, fructose, lactose, Sucrose, maltose, Sorbitol, mannitol, 
etc. 
In further embodiments, the present invention may con 
cern the use of a pharmaceutical lipid vehicle composition 
that includes an engineered methioninase, one or more 
lipids, and an aqueous solvent. As used herein, the term 
“lipid’ will be defined to include any of a broad range of 30 
Substances that is characteristically insoluble in water and 
extractable with an organic solvent. This broad class of 
compounds is well known to those of skill in the art, and as 
the term “lipid' is used herein, it is not limited to any 
particular structure. Examples include compounds that con 
tain long-chain aliphatic hydrocarbons and their derivatives. 
A lipid may be naturally occurring or synthetic (i.e., 
designed or produced by man). However, a lipid is usually 
a biological Substance. Biological lipids are well known in 
the art, and include for example, neutral fats, phospholipids, 
phosphoglycerides, steroids, terpenes, lysolipids, gly 
cosphingolipids, glycolipids, Sulphatides, lipids with ether 
and ester-linked fatty acids, polymerizable lipids, and com 
binations thereof. Of course, compounds other than those 
specifically described herein that are understood by one of 
skill in the art as lipids are also encompassed by the 
compositions and methods. 
One of ordinary skill in the art would be familiar with the 
range of techniques that can be employed for dispersing a 
composition in a lipid vehicle. For example, the engineered 
methioninase or a fusion protein thereof may be dispersed in 
a solution containing a lipid, dissolved with a lipid, emul 
sified with a lipid, mixed with a lipid, combined with a lipid, 
covalently bonded to a lipid, contained as a suspension in a 
lipid, contained or complexed with a micelle or liposome, or 
otherwise associated with a lipid or lipid structure by any 
means known to those of ordinary skill in the art. The 
dispersion may or may not result in the formation of 
liposomes. 
The actual dosage amount of a composition administered 
to an animal patient can be determined by physical and 
physiological factors. Such as body weight, severity of 
condition, the type of disease being treated, previous or 
concurrent therapeutic interventions, idiopathy of the 
patient, and on the route of administration. Depending upon 
the dosage and the route of administration, the number of 










amount may vary according to the response of the Subject. 
The practitioner responsible for administration will, in any 
event, determine the concentration of active ingredient(s) in 
a composition and appropriate dose(s) for the individual 
Subject. 
In certain embodiments, pharmaceutical compositions 
may comprise, for example, at least about 0.1% of an active 
compound. In other embodiments, an active compound may 
comprise between about 2% to about 75% of the weight of 
the unit, or between about 25% to about 60%, for example, 
and any range derivable therein. Naturally, the amount of 
active compound(s) in each therapeutically useful compo 
sition may be prepared in Such a way that a suitable dosage 
will be obtained in any given unit dose of the compound. 
Factors, such as solubility, bioavailability, biological half 
life, route of administration, product shelf life, as well as 
other pharmacological considerations, will be contemplated 
by one skilled in the art of preparing Such pharmaceutical 
formulations, and as such, a variety of dosages and treatment 
regimens may be desirable. 
In other non-limiting examples, a dose may also comprise 
from about 1 microgram/kg/body weight, about 5 micro 
gram/kg/body weight, about 10 microgram/kg/body weight, 
about 50 microgram/kg/body weight, about 100 microgram/ 
kg/body weight, about 200 microgram/kg/body weight, 
about 350 microgram/kg/body weight, about 500 micro 
gram/kg/body weight, about 1 milligram/kg/body weight, 
about 5 milligram/kg/body weight, about 10 milligram/kg/ 
body weight, about 50 milligram/kg/body weight, about 100 
milligram/kg/body weight, about 200 milligram/kg/body 
weight, about 350 milligram/kg/body weight, about 500 
milligram/kg/body weight, to about 1000 milligram/kg/body 
weight or more per administration, and any range derivable 
therein. In non-limiting examples of a derivable range from 
the numbers listed herein, a range of about 5 milligram/kg/ 
body weight to about 100 milligram/kg/body weight, about 
5 microgram/kg/body weight to about 500 milligram/kg/ 
body weight, etc., can be administered, based on the num 
bers described above. 
XI. COMBINATION TREATMENTS 
In certain embodiments, the compositions and methods of 
the present embodiments involve administration of an engi 
neered methioninase in combination with a second or addi 
tional therapy. Such therapy can be applied in the treatment 
of any disease that is associated with methionine depen 
dency. For example, the disease may be cancer. 
The methods and compositions, including combination 
therapies, enhance the therapeutic or protective effect, and/ 
or increase the therapeutic effect of another anti-cancer or 
anti-hyperproliferative therapy. Therapeutic and prophylac 
tic methods and compositions can be provided in a com 
bined amount effective to achieve the desired effect, such as 
the killing of a cancer cell and/or the inhibition of cellular 
hyperproliferation. This process may involve contacting the 
cells with both an engineered methioninase and a second 
therapy. A tissue, tumor, or cell can be contacted with one or 
more compositions or pharmacological formulation(s) com 
prising one or more of the agents (i.e., an engineered 
methioninase or an anti-cancer agent), or by contacting the 
tissue, tumor, and/or cell with two or more distinct compo 
sitions or formulations, wherein one composition provides 
1) an engineered methioninase, 2) an anti-cancer agent, or 3) 
both an engineered methioninase and an anti-cancer agent. 
Also, it is contemplated that Such a combination therapy can 
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be used in conjunction with chemotherapy, radiotherapy, 
Surgical therapy, or immunotherapy. 
The terms “contacted” and “exposed,” when applied to a 
cell, are used herein to describe the process by which a 
therapeutic construct and a chemotherapeutic or radiothera 
peutic agent are delivered to a target cell or are placed in 
direct juxtaposition with the target cell. To achieve cell 
killing, for example, both agents are delivered to a cell in a 
combined amount effective to kill the cell or prevent it from 
dividing. 
An engineered methioninase may be administered before, 
during, after, or in various combinations relative to an 
anti-cancer treatment. The administrations may be in inter 
vals ranging from concurrently to minutes to days to weeks. 
In embodiments where the engineered methioninase is pro 
vided to a patient separately from an anti-cancer agent, one 
would generally ensure that a significant period of time did 
not expire between the time of each delivery, such that the 
two compounds would still be able to exert an advanta 
geously combined effect on the patient. In Such instances, it 
is contemplated that one may provide a patient with the 
engineered methioninase and the anti-cancer therapy within 
about 12 to 24 or 72 h of each other and, more particularly, 
within about 6-12 h of each other. In some situations it may 
be desirable to extend the time period for treatment signifi 
cantly where several days (2, 3, 4, 5, 6, or 7) to several weeks 
(1, 2, 3, 4, 5, 6, 7, or 8) lapse between respective adminis 
trations. 
In certain embodiments, a course of treatment will last 
1-90 days or more (this such range includes intervening 
days). It is contemplated that one agent may be given on any 
day of day 1 to day 90 (this such range includes intervening 
days) or any combination thereof, and another agent is given 
on any day of day 1 to day 90 (this such range includes 
intervening days) or any combination thereof. Within a 
single day (24-hour period), the patient may be given one or 
multiple administrations of the agent(s). Moreover, after a 
course of treatment, it is contemplated that there is a period 
of time at which no anti-cancer treatment is administered. 
This time period may last 1-7 days, and/or 1-5 weeks, and/or 
1-12 months or more (this such range includes intervening 
days), depending on the condition of the patient, Such as 
their prognosis, strength, health, etc. It is expected that the 
treatment cycles would be repeated as necessary. 
Various combinations may be employed. For the example 
below an engineered methioninase is “A” and an anti-cancer 
therapy is “B”: 
ABAB, ABBBAAABAB,BBAAABBBB, ABB 
BBBAB.BABAABBAB, ABAB,B, ABBAA 
BAB, ABAABAAABBAAAABAAAABA 
Administration of any compound or therapy of the present 
embodiments to a patient will follow general protocols for 
the administration of Such compounds, taking into account 
the toxicity, if any, of the agents. Therefore, in some 
embodiments there is a step of monitoring toxicity that is 
attributable to combination therapy. 
A. Chemotherapy 
A wide variety of chemotherapeutic agents may be used 
in accordance with the present embodiments. The term 
“chemotherapy” refers to the use of drugs to treat cancer. A 
“chemotherapeutic agent' is used to connote a compound or 
composition that is administered in the treatment of cancer. 
These agents or drugs are categorized by their mode of 













they affect the cell cycle. Alternatively, an agent may be 
characterized based on its ability to directly cross-link DNA, 
to intercalate into DNA, or to induce chromosomal and 
mitotic aberrations by affecting nucleic acid synthesis. 
Examples of chemotherapeutic agents include alkylating 
agents, such as thiotepa and cyclosphosphamide; alkyl Sul 
fonates, such as buSulfan, improSulfan, and piposulfan; 
aziridines, such as benzodopa, carboquone, meturedopa, and 
uredopa; ethylenimines and methylamelamines, including 
altretamine, triethylenemelamine, trietylenephosphoramide, 
triethiylenethiophosphoramide, and trimethylolomelamine; 
acetogenins (especially bullatacin and bullatacinone); a 
camptothecin (including the synthetic analogue topotecan); 
bryostatin: cally statin: CC-1065 (including its adozelesin, 
carzelesin and bizelesin synthetic analogues); cryptophycins 
(particularly cryptophycin 1 and cryptophycin 8); dolastatin: 
duocarmycin (including the synthetic analogues, KW-2189 
and CB1-TM1); eleutherobin: pancratistatin: a sarcodictyin: 
spongistatin: nitrogen mustards, such as chlorambucil, chlo 
rnaphazine, cholophosphamide, estramustine, ifosfamide, 
mechlorethamine, mechlorethamine oxide hydrochloride, 
melphalan, novembichin, phenesterine, prednimustine, tro 
fosfamide, and uracil mustard; nitroSureas, such as carmus 
tine, chlorozotocin, fotemustine, lomustine, nimustine, and 
ranimnustine; antibiotics, such as the enediyne antibiotics 
(e.g., calicheamicin, especially calicheamicin gammalI and 
calicheamicin omegall); dynemicin, including dynemicin 
A. bisphosphonates, such as clodronate; an esperamicin; as 
well as neocarzinostatin chromophore and related chro 
moprotein enediyne antiobiotic chromophores, aclacino 
mysins, actinomycin, authramycin, aZaserine, bleomycins, 
cactinomycin, carabicin, carminomycin, carZinophilin, 
chromomycinis, dactinomycin, daunorubicin, detorubicin, 
6-diazo-5-oxo-L-norleucine, doxorubicin (including mor 
pholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyr 
rolino-doxorubicin and deoxydoxorubicin), epirubicin, eso 
rubicin, idarubicin, marcellomycin, mitomycins, such as 
mitomycin C, mycophenolic acid, nogalamycin, olivomy 
cins, peplomycin, potfiromycin, puromycin, quelamycin, 
rodorubicin, Streptonigrin, Streptozocin, tubercidin, uben 
imex, Zinostatin, and Zorubicin; anti-metabolites, such as 
methotrexate and 5-fluorouracil (5-FU); folic acid ana 
logues, such as denopterin, pteropterin, and trimetrexate; 
purine analogs, such as fludarabine, 6-mercaptopurine, thia 
miprine, and thioguanine; pyrimidine analogs, such as ancit 
abine, azacitidine, 6-azauridine, carmofur, cytarabine, dide 
oxyuridine, doxifluridine, enocitabine, and floxuridine: 
androgens, such as calusterone, dromoStanolone propionate, 
epitiostanol, mepitioStane, and testolactone; anti-adrenals, 
Such as mitotane and triloStane; folic acid replenisher, Such 
as frolinic acid; aceglatone; aldophosphamide glycoside; 
aminolevulinic acid; eniluracil; amsacrine; bestrabucil; 
bisantrene; ediatraxate; defofamine; demecolcine; diazi 
quone; elformithine; elliptinium acetate; an epothilone; eto 
glucid: gallium nitrate; hydroxyurea; lentinan; lonidainine; 
maytansinoids, Such as maytansine and ansamitocins; mito 
guaZone; mitoxantrone; mopidanmol; nitraerine; pentosta 
tin: phenamet; pirarubicin; losoxantrone; podophyllinic 
acid; 2-ethylhydrazide; procarbazine; PSKpolysaccharide 
complex; razoxane; rhizoxin; sizofiran; Spirogermanium; 
tenuaZonic acid; triaziquone; 2.2.2"-trichlorotriethylamine; 
trichothecenes (especially T-2 toxin, Verracurin A, roridin A 
and anguidine); urethan; vindesine; dacarbazine; manno 
mustine; mitobronitol; mitolactol; pipobroman, gacytosine; 
arabinoside ("Ara-C); cyclophosphamide; taxoids, e.g., 
paclitaxel and docetaxel gemcitabine; 6-thioguanine; mer 
captopurine; platinum coordination complexes, such as cis 
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platin, oxaliplatin, and carboplatin: vinblastine; platinum; 
etoposide (VP-16); ifosfamide; mitoxantrone; Vincristine: 
Vinorelbine; novantrone; teniposide; ediatrexate; daunomy 
cin; aminopterin: Xeloda; ibandronate; irinotecan (e.g., CPT 
11); topoisomerase inhibitor RFS 2000; difluorometlhylor 
nithine (DMFO); retinoids, such as retinoic acid; 
capecitabine; carboplatin, procarbazine, plicomycin, gem 
citabien, navelbine, farnesyl-protein tansferase inhibitors, 
transplatinum, and pharmaceutically acceptable salts, acids, 
or derivatives of any of the above. 
B. Radiotherapy 
Other factors that cause DNA damage and have been used 
extensively include what are commonly known as Y-rays, 
X-rays, and/or the directed delivery of radioisotopes to 
tumor cells. Other forms of DNA damaging factors are also 
contemplated. Such as microwaves, proton beam irradiation 
(U.S. Pat. Nos. 5,760,395 and 4,870.287), and UV-irradia 
tion. It is most likely that all of these factors affect a broad 
range of damage on DNA, on the precursors of DNA, on the 
replication and repair of DNA, and on the assembly and 
maintenance of chromosomes. Dosage ranges for X-rays 
range from daily doses of 50 to 200 roentgens for prolonged 
periods of time (3 to 4 wk), to single doses of 2000 to 6000 
roentgens. Dosage ranges for radioisotopes vary widely, and 
depend on the half-life of the isotope, the strength and type 
of radiation emitted, and the uptake by the neoplastic cells. 
C. Immunotherapy 
The skilled artisan will understand that immunotherapies 
may be used in combination or in conjunction with methods 
of the embodiments. In the context of cancer treatment, 
immunotherapeutics, generally, rely on the use of immune 
effector cells and molecules to target and destroy cancer 
cells. Rituximab (RITUXANR) is such an example. The 
immune effector may be, for example, an antibody specific 
for some marker on the surface of a tumor cell. The antibody 
alone may serve as an effector of therapy or it may recruit 
other cells to actually affect cell killing. The antibody also 
may be conjugated to a drug or toxin (chemotherapeutic, 
radionuclide, ricin A chain, cholera toxin, pertussis toxin, 
etc.) and serve merely as a targeting agent. Alternatively, the 
effector may be a lymphocyte carrying a surface molecule 
that interacts, either directly or indirectly, with a tumor cell 
target. Various effector cells include cytotoxic T cells and 
NK cells. 
In one aspect of immunotherapy, the tumor cell must bear 
Some marker that is amenable to targeting, i.e., is not present 
on the majority of other cells. Many tumor markers exist and 
any of these may be suitable for targeting in the context of 
the present embodiments. Common tumor markers include 
CD20, carcinoembryonic antigen, tyrosinase (p97), gp68, 
TAG-72, HMFG, Sialyl Lewis Antigen, MucA. Much3, 
PLAP laminin receptor, erb B, and p155. An alternative 
aspect of immunotherapy is to combine anticancer effects 
with immune stimulatory effects. Immune stimulating mol 
ecules also exist including: cytokines, such as IL-2, IL-4, 
IL-12, GM-CSF, gamma-IFN, chemokines, such as MIP-1, 
MCP-1, IL-8, and growth factors, such as FLT3 ligand. 
Examples of immunotherapies currently under investiga 
tion or in use are immune adjuvants, e.g., Mycobacterium 
bovis, Plasmodium falciparum, dinitrochlorobenzene, and 
aromatic compounds (U.S. Pat. Nos. 5,801,005 and 5,739, 
169: Hui and Hashimoto, 1998; Christodoulides et al., 
1998): cytokine therapy, e.g., interferons C, B, and Y, IL-1, 
GM-CSF, and TNF (Bukowski et al., 1998; Davidson et al., 
1998: Hellstrand et al., 1998); gene therapy, e.g., TNF, IL-1, 
IL-2, and p53 (Qin et al., 1998; Austin-Ward and Villaseca, 













clonal antibodies, e.g., anti-CD20, anti-ganglioside GM2, 
and anti-p185 (Hollander, 2012: Hanibuchi et al., 1998: U.S. 
Pat. No. 5,824.311). It is contemplated that one or more 
anti-cancer therapies may be employed with the antibody 
therapies described herein. 
D. Surgery 
Approximately 60% of persons with cancer will undergo 
Surgery of Some type, which includes preventative, diagnos 
tic or staging, curative, and palliative Surgery. Curative 
Surgery includes resection in which all or part of cancerous 
tissue is physically removed, excised, and/or destroyed and 
may be used in conjunction with other therapies, such as the 
treatment of the present embodiments, chemotherapy, radio 
therapy, hormonal therapy, gene therapy, immunotherapy, 
and/or alternative therapies. Tumor resection refers to physi 
cal removal of at least part of a tumor. In addition to tumor 
resection, treatment by Surgery includes laser Surgery, cryo 
Surgery, electroSurgery, and microscopically-controlled Sur 
gery (Mohs Surgery). 
Upon excision of part or all of cancerous cells, tissue, or 
tumor, a cavity may be formed in the body. Treatment may 
be accomplished by perfusion, direct injection, or local 
application of the area with an additional anti-cancer 
therapy. Such treatment may be repeated, for example, every 
1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks 
or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These 
treatments may be of varying dosages as well. 
E. Other Agents 
It is contemplated that other agents may be used in 
combination with certain aspects of the present embodi 
ments to improve the therapeutic efficacy of treatment. 
These additional agents include agents that affect the 
upregulation of cell Surface receptors and GAP junctions, 
cytostatic and differentiation agents, inhibitors of cell adhe 
Sion, agents that increase the sensitivity of the hyperprolif 
erative cells to apoptotic inducers, or other biological agents. 
Increases in intercellular signaling by elevating the number 
of GAP junctions would increase the anti-hyperproliferative 
effects on the neighboring hyperproliferative cell popula 
tion. In other embodiments, cytostatic or differentiation 
agents can be used in combination with certain aspects of the 
present embodiments to improve the anti-hyperproliferative 
efficacy of the treatments. Inhibitors of cell adhesion are 
contemplated to improve the efficacy of the present embodi 
ments. Examples of cell adhesion inhibitors are focal adhe 
sion kinase (FAKs) inhibitors and Lovastatin. It is further 
contemplated that other agents that increase the sensitivity 
of a hyperproliferative cell to apoptosis, such as the antibody 
c225, could be used in combination with certain aspects of 
the present embodiments to improve the treatment efficacy. 
XII. KITS 
Certain aspects of the present invention may provide kits, 
Such as therapeutic kits. For example, a kit may comprise 
one or more pharmaceutical composition as described herein 
and optionally instructions for their use. Kits may also 
comprise one or more devices for accomplishing adminis 
tration of such compositions. For example, a subject kit may 
comprise a pharmaceutical composition and catheter for 
accomplishing direct intravenous injection of the composi 
tion into a cancerous tumor. In other embodiments, a subject 
kit may comprise pre-filled ampoules of an engineered 
methioninase, optionally formulated as a pharmaceutical, or 
lyophilized, for use with a delivery device. 
Kits may comprise a container with a label. Suitable 
containers include, for example, bottles, vials, and test tubes. 
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The containers may be formed from a variety of materials, 
Such as glass or plastic. The container may hold a compo 
sition that includes an engineered methioninase that is 
effective for therapeutic or non-therapeutic applications, 
such as described above. The label on the container may 
indicate that the composition is used for a specific therapy or 
non-therapeutic application, and may also indicate direc 
tions for either in vivo or in vitro use, such as those 
described above. The kit of the invention will typically 
comprise the container described above and one or more 
other containers comprising materials desirable from a com 
mercial and user Standpoint, including buffers, diluents, 
filters, needles, syringes, and package inserts with instruc 
tions for use. 
XIII. EXAMPLES 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
Example 1 
Cystathionine-y-Lyase Engineered for 
Methionine-y-Lyase Activity 
CGL is a tetramer that catalyzes the last step in the 
mammalian transsulfuration pathway (Rao et al., 1990). 
CGL catalyzes the conversion of L-cystathionine to L-cys 
teine, alpha-ketobutyrate, and ammonia. The human CGL 
(hCGL) clNA has previously been cloned and expressed, 
but with relatively low yields (-5 mg/L culture) (Lu et al., 
1992; Steegborn et al., 1999). Using sequence and structural 
alignments of CGL and MGL enzymes as a guide. hCGL 
was converted to an enzyme for the efficient degradation of 
methionine. 
Example 2 
Gene Synthesis and Expression of Improved 
Modified Human Cystathionine-y-Lyase 
The human cyStathionine-y-lyase gene contains multiple 
codons that are rarely utilized in E. coli and can interfere 
with expression. Thus, in order to optimize protein expres 
sion in E. coli, the respective genes were assembled with 
codon optimized oligonucleotides designed using DNA 
Works software (Hoover et al., 2002). Each construct con 
tains an N-terminal Nicol restriction site, an in-frame N-ter 
minal His tag, and a C-terminal EcoRI site for simplifying 
cloning. After cloning into a pET28a vector (Novagen), E. 
coli (BL21) containing an appropriate cystathionase expres 
sion vector were grown at 37° C. using Terrific Broth (TB) 
media containing 50 ug/mL. kanamycin in shaker flasks at 
250 rpm until reaching an ODoo of ~0.5-0.6. At this point 
the cultures were switched to a shaker at 25° C., induced 
with 0.5 mM IPTG, and allowed to express protein for an 
additional 12 h. Cell pellets were then collected by centrifu 













10 mM imidazole/300 mM. NaCl, pH 8). After lysis by a 
French pressure cell, lysates were centrifuged at 20,000xg 
for 20 min at 4°C., and the resulting Supernatant applied to 
a nickel IMAC column, washed with 10-20 column volumes 
of IMAC buffer, and then eluted with an IMAC elution 
buffer (50 mM NaPO/250 mM imidazole/300 mM. NaCl, 
pH 8). Fractions containing enzyme were then incubated 
with 10 mM pyridoxal-5'-phosphate (PLP) for an hour at 25° 
C. Using a 10,000 MWCO centrifugal filter device (AMI 
CONR), proteins were then buffer exchanged several times 
into a 100 mM PBS, 10% glycerol, pH 7.3 solution. Enzyme 
aliquots were then flash frozen in liquid nitrogen and stored 
at -80° C. CGL and CGL variants purified in this manner 
were >95% homogeneous as assessed by SDS-PAGE and 
coomassie staining. The yield was calculated to be ~400 
mg/L culture based upon the calculated extinction coeffi 
cient, so 29,870 M'cm in a final buffer concentration 
of 6 M guanidinium hydrochloride, 20 mM phosphate 
buffer, pH 6.5 (Gill and von Hippel, 1989). 
Example 3 
96-Well Plate Screen for Methionine-y-Lyase 
Activity and Ranking Clones 
Both MGL and CGL produce 2-ketobutanoic acid from 
their respective substrates. A colorimetric assay for the 
detection of C.-keto acids using 3-methylbenzothiazolin-2- 
one hydrazone (MBTH) (Takakura et al., 2004) was scaled 
to a 96-well plate format for screening small libraries and for 
ranking clones with the greatest METase (methionine-y- 
lyase) activity. This plate screen provides a facile method for 
picking the most active clones from the mutagenic libraries. 
Clones displaying greater activity than parental controls are 
selected for further characterization, thus eliminating the 
need to purify more than a few variants for kinetic analysis. 
Single colonies containing mutagenized hCGL, hCGL or 
pMGL were picked into 96-well culture plates containing 75 
LL of TB media/well containing 50 ug/mL, kanamycin. 
These cultures were then grown at 37° C. on a plate shaker 
until reaching an ODoo of -0.8-1. After cooling to 25°C., 
an additional 75 uL of media/well containing 50 lug/mL 
kanamycin and 0.5 mM IPTG was added. Expression was 
performed at 25°C. with shaking for 2 h, following which 
100 uL of culture/well was transferred to a 96-well assay 
plate. The assay plates were then centrifuged to pellet the 
cells, the media was removed, and the cells were lysed by 
addition of 50 L/well of B-PER(R) protein extraction 
reagent (Pierce). After clearing by centrifugation, the lysate 
was incubated with 5 mM L-Met at 37° C. for 10-12 h. The 
reaction was then derivatized by addition of 3 parts of 0.03% 
MBTH solution in 1 M sodium acetate, pH 5. The plates 
were heated at 50° C. for 40 min and after cooling were read 
at 320 nm in a microtiter plate reader. 
Example 4 
Library Design for Generating Improved 
Methionine Degrading Variants Derived from 
hCGL-E59N-R119L-E339V 
The gene for the hCGL-E59N-R119L-E339V (hCGL 
NLV) methionine degrading enzyme was used as a starting 
point to generate further variants with improvements in 
activity. Amino acid sequence alignments were generated 
using MGL and CGL sequences from various organisms. 
Regions selected for mutagenesis were identified at specific 
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alignment sites where the MGL enzymes all had one con 
served residue and the CGL enzymes all had a different 
conserved residue. Although MGL and CGL have highly 
homologous structures they do not degrade each other's 
respective Substrate, thus phylogenetically conserved amino 
acid sequence differences between MGL and CGL enzymes 
can indicate residues that are important for degrading their 
respective substrate. Libraries were generated by overlap 
extension PCR using oligonucleotides containing either a 
codon for the parent hCGL-NLV template coding for a 
conserved residue or a codon for the corresponding MGL 
conserved residue. The final assembled PCR products were 
digested with NcoI and EcoRI and ligated into pET28a 
vector with T4 DNA ligase. The resulting ligations were 
transformed directly into E. coli (BL21) and plated on 
LB-kanamycin plates for Subsequent Screening as described 
in Example 3. Two times more colonies than the theoretical 
diversity of the libraries (i.e., all possible gene sequences 
encoded by the library) were screened. Clones displaying 
greater activity than the parent hCGL-NLV variant were 
isolated and sequenced to identify the mutations conferring 
improved activity. Clones with improved L-methionine 
degrading activity were used as templates in iterative rounds 
of mutagenesis as described. 
Example 5 
Characterization of Improved Human Methionine 
Degrading Variants 
After several rounds of mutagenesis and screening as 
described in Examples 3 and 4, five amino acid positions in 
addition to the original three mutation sites (i.e. E59N 
R119L-E339V) were found to confer improved methionine 
degrading activity compared to hCGL-NLV (SEQ ID NO: 
2). These additional positions are located at hCGL (SEQ ID 
NO: 1) residues 63, 91, 268, 311, and 353 (see, FIG. 1). 
Mutation of one or more of these positions to S63L, L91M, 
K268R, T311G, and I353S, in combination with mutations 
of residues at positions 59, 119, and 339, resulted in 
improved ki/K values for degrading L-methionine com 
pared to hCGL-NLV. In particular, the variants containing 
amino acid substitutions corresponding to SEQ ID NO: 3, 
hCGL-E59N-S63L-L91 M-R119L-K268R-T311G-E339V 
I353S (hCGL-8mut-1); SEQ ID NO: 4, hCGL-E59I-S63L 
L91M-R119L-K268R-T311G-E339V-I353S (hCGL-8mut 
2); SEQ ID NO: 5, hCGL-E59N-S63L-L91M-R119A 
K268R-T311G-E339V-I353S (hCGL-8mut-3); and SEQ ID 
NO: 6, hCGL-E59I-S63L-L91 M-R119A-K268R-T311G 
E339V-I353S (hCGL-8mut-4) were shown to have the high 
est k/K values for degrading L-methionine. These vari 
ants (hCGL-8mut-(1-4)) were purified to greater than 95% 
homogeneity as assessed by SDS-PAGE as described in 
Example 2 and kinetically characterized for their ability to 
degrade L-Met in a 100 mM PBS buffer at pH 7.3 and 37° 
C. using a 1 mL scale MBTH assay similar to that described 
in Example 3. 
TABLE 1. 
Comparison of Michaelis-Menten kinetics of L-methionine degradation at 
pH 7.3 and 37° C. using hCGL, h0GL-NLV, and improved variants 
hCGL-8mut(1-4). 
Variant k.a. s." Ka mM k/K SM.' 
hCGL O O O 
hCGL-NLV 7.9 14 S60 















Comparison of Michaelis-Menten kinetics of L-methionine degradation at 
pH 7.3 and 37° C. using hCGL, h0GL-NLV, and improved variants 
hCGL-8mut(1-4). 
Variant k.a. s." Ka mM k/K s'M' 
hCGL-8mut-2 7.1 1.4 5070 
hCGL-8mut-3 ND ND ND 
hCGL-8mut-4 9.8 1.8 5440 
ND = not determined 
Example 6 
Cytotoxicity of hCGL-8Mut-1 Against Tumor Cell 
Lines 
The in vitro cytotoxicity of hCGL-8mut-1 was assessed 
against melanoma cell line A375 and prostate cancer cell 
lines DU145 and PC3. Cells were seeded at 3000 cells/well 
in 96-well culture plates in DMEM media for the A375 cells 
or RPMI-1640 media for the prostate tumor cell lines and 
allowed to grow for 24 h before treatment with varying 
concentrations of enzyme. After 5 days of treatment, pro 
liferation was measured using the (3-(4,5-dimethylthiazol 
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H 
tetrazolium (MTS) assay. Analysis of the resulting data for 
A375 yielded an apparent ICs value of 0.08 uM and 
apparent ICs values of 0.21 uM for DU145 and 0.25uM for 
PC3 prostate tumor cells (FIG. 2). 
Example 7 
Pharmacological Preparation of hCGL-8mut-1 
The hCGL-8mut-1 enzyme was purified as described in 
Example 2 with one exception: after binding to the IMAC 
column, the protein was washed extensively (90-100 column 
volumes) with an IMAC buffer containing 0.1% TRITONR) 
114. Then the column was washed with 10-20 column 
volumes of IMAC buffer and eluted with an IMAC elution 
buffer (50 mM NaPO/250 mM imidazole/300 mM. NaCl, 
pH 8). Washing with TRITONR) 114 was employed for 
endotoxin removal. The purified protein was subjected to 
buffer exchange into a 100 mM NaPO buffer at pH 8.3 
using a 10,000 MWCO filtration device (Amicon). Subse 
quently, PLP was added at a concentration of 10 mM and the 
protein was incubated for 1 h at 25° C. Methoxy PEG 
Succinimidyl Carboxymethyl Ester 5000 MW (JenKem 
Technology) was then added to hCGL-8mut-1 at an 80:1 
molar ratio and allowed to react for 1 h at 25° C. under 
constant stirring. The resulting mixture was extensively 
buffer exchanged (PBS with 10% glycerol) using a 100,000 
MWCO filtration device (Amicon), and sterilized with a 0.2 
micron syringe filter (VWR). All PEGylated enzymes were 
analyzed for lipopolysaccharide (LPS) content using a 
Limulus Amebocyte Lysate (LAL) kit (Cape Cod Incorpo 
rated). 
Example 8 
Serum Stability of PEGylated hCGL-8mut-1 
The serum stability of PEGylated hCGL-8mut-1 was 
tested by incubation of the enzyme in pooled human serum 
at 37° C. at a final concentration of 10 uM. At different time 
points, aliquots were withdrawn and tested for activity using 
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the DTNB assay as described in U.S. Pat. Publ. 2011/ 
0200576, which is incorporated herein by reference in its 
entirety. After plotting the data, PEGylated hCGL-8mut-1 
was calculated to have a half-life (Tos) of 1014 h (FIG. 3). 
Example 9 
Pharmacodymanic Analysis of PEGylated 
hCGL-8Mut-1 in Mice 
To assess the efficacy of the engineered human methio 
nine degrading enzymes disclosed in Examples 4-7 above in 
clearing L-methionine in a mouse model, three groups of 
three animals each were administered 50 mg/kg of PEG 
hCGL-8mut-1 by tail vein injection, while being maintained 
on a normal diet. Groups were sacrificed at time points 
corresponding to 8, 24, and 48 h by cardiac Venipuncture for 
serum collection. The serum samples were then analyzed for 
L-methionine content by derivatization with o-phthalalde 
hyde (OPA) followed by high performance liquid chroma 
tography (HPLC) essentially as described by Agilent Tech 
nologies (on the world wide web at chem.agilent.com/ 
Library/datasheets/Public/5980-3088.PDF). This dosing 
scheme using PEG-hCGL-8mut-1 enabled depletion of 
L-methionine to levels lower than 5uM for over 15 h (FIG. 
4). In contrast, administration of 200 mg/kg of the PEGy 
lated hCGL-NLV to mice on a normal diet only lowered 
serum L-methionine to ~10 uM for 4 h (FIG. 5). 
All of the methods disclosed and claimed herein can be 
made and executed without undue experimentation in light 
of the present disclosure. While the compositions and meth 
ods of this invention have been described in terms of 
preferred embodiments, it will be apparent to those of skill 
in the art that variations may be applied to the methods and 
in the steps or in the sequence of steps of the method 
described herein without departing from the concept, spirit 
and scope of the invention. More specifically, it will be 
apparent that certain agents which are both chemically and 
physiologically related may be substituted for the agents 
described herein while the same or similar results would be 
achieved. All such similar substitutes and modifications 
apparent to those skilled in the art are deemed to be within 
the spirit, scope and concept of the invention as defined by 
the appended claims. 
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SEO ID NO 1 
LENGTH: 
TYPE PRT 
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- Continued 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Glu Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ile Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 2 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 2 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Ser Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Lieu Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Gly Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Ser Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Lys His Phe Lys Asn 
26 O 265 27 O 
US 9,481,877 B2 
43 
- Continued 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Thr Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ile Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 3 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 3 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Gly Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Ser Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
44 
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- Continued 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 4 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 4 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Gly Cys Ala His Ile Val 
1.65 17O 17s 
46 
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- Continued 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Ser Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thr Lieu. Ile Arg Lieu Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 5 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 5 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Ala Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
48 
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- Continued 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Gly Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Ser Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thr Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 6 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 6 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
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- Continued 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Ala Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Gly Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Ser Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser ASn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 7 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Pongo abelii 
<4 OO > SEQUENCE: 7 
Met Glin Glu Lys Glu Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Glu Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Pro Ser Val Thr Phe Lys 































































































































<210s, SEQ ID NO 8 
&211s LENGTH: 
212. TYPE : 
<213> ORGANISM: Macaca fascicularis 
PRT 
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57 
- Continued 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Pan troglodytes 
<4 OOs, SEQUENCE: 9 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Glu Tyr Ser Arg Ser Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Lieu Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Arg Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
ASn Pro Thr Gln Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Lys His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Thr Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Glu Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ile Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
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- Continued 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 10 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Pan paniscus 
<4 OOs, SEQUENCE: 10 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Lys Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Glu Tyr Ser Arg Ser Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Lieu Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Arg Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Ile Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Lys His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Thr Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Glu Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
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- Continued 
Ile Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 11 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 11 
Met Glin Glu Lys Glu Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Glu Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Pro Ser Val Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Ala Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Gln Lys Met Thr Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Lieu Ala Lieu. Gly Ala Asp Ile Cys Met Cys 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. Tyr Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. Glin Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
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- Continued 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Val Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Lys Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 12 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 12 
Met Glin Glu Lys Glu Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Glu Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Pro Ser Val Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Ala Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Gln Lys Met Thr Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Lieu Ala Lieu. Gly Ala Asp Ile Cys Met Cys 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. Tyr Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 



















































































































SEQ ID NO 13 
LENGTH: 
TYPE : 
ORGANISM: Artificial Sequence 
FEATURE: 
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- Continued 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. Tyr Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. Glin Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Val Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Lys Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 14 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 14 
Met Glin Glu Lys Glu Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Glu Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Pro Ile Ser Pro Ser Val Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Ala Gly Thr Asn Ala Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
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69 
- Continued 
Asn Pro Thr Gln Lys Met Thr Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Lieu Ala Lieu. Gly Ala Asp Ile Cys Met Cys 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. Tyr Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. Glin Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Val Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Lys Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 15 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 15 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Glu Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Leu. Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Glin Ala Ala Pro Gly Gln His Ser Gly Phe ASn Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
US 9,481,877 B2 
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- Continued 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Val Lieu Lys Met Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Lys Arg Gly Asp Ile Ile Lieu Val Val Asp Asn. Thir Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Lieu Ala Lieu. Gly Ala Asp Ile Cys Met Cys 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Arg Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Lieu. Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Gly Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Ala Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Ile Thr Phe Tyr Ile Llys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Val Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Pro Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Lys 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Asn 
4 OS 
<210s, SEQ ID NO 16 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 16 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Glu Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Leu. Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Glin Ala Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
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- Continued 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Val Lieu Lys Met Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Lys Arg Gly Asp Ile Ile Lieu Val Val Asp Asn. Thir Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Lieu Ala Lieu. Gly Ala Asp Ile Cys Met Cys 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Arg Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Lieu. Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Gly Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Ala Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Ile Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Val Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Pro Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Lys 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Asn 
4 OS 
<210s, SEQ ID NO 17 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 17 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 











































































































































<210s, SEQ ID NO 18 
&211s LENGTH: 
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- Continued 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 18 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Glu Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Val Val Pro Leu. Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Glin Ala Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Ala Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
ASn Pro Val Lieu Lys Met Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Lys Arg Gly Asp Ile Ile Lieu Val Val Asp Asn. Thir Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Lieu Ala Lieu. Gly Ala Asp Ile Cys Met Cys 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Arg Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Lieu. Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Gly Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Ala Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Ile Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Val Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Pro Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Lys 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
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- Continued 
385 390 395 4 OO 
Ser Gly Ser His Asn 
4 OS 
<210s, SEQ ID NO 19 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 19 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
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- Continued 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 2O 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
ASn Pro Thr Arg ASn Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
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- Continued 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 21 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 21 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Gln Trp 
2O 25 3O 
Thir Ser Arg Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Ala Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
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- Continued 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 22 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 22 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Arg Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Ala Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
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- Continued 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Met Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 23 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 23 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Lys Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
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- Continued 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Ile Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35 O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 24 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 24 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Lys Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Ile Tyr Ser Arg Lieu. Gly 
SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
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1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Lieu. Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Ile Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 25 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 25 
Met Glin Glu Lys Asp Ala Ser Ser Glin Gly Phe Leu Pro His Phe Glin 
1. 5 1O 15 
His Phe Ala Thr Glin Ala Ile His Val Gly Glin Asp Pro Glu Glin Trp 
2O 25 3O 
Thir Ser Lys Ala Lieu Val Pro Pro Ile Ser Leu Ser Thr Thr Phe Lys 
35 4 O 45 
Gln Gly Ala Pro Gly Glin His Ser Gly Phe Asn Tyr Ser Arg Lieu. Gly 
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SO 55 6 O 
Asn Pro Thir Arg Asn. Cys Lieu. Glu Lys Ala Val Ala Ala Lieu. Asp Gly 
65 70 7s 8O 
Ala Lys Tyr Cys Lieu Ala Phe Ala Ser Gly Met Ala Ala Thr Val Thr 
85 90 95 
Ile Thr His Lieu Lleu Lys Ala Gly Asp Glin Ile Ile Cys Met Asp Asp 
1OO 105 11 O 
Val Tyr Gly Gly Thr Asn Ala Tyr Phe Arg Glin Val Ala Ser Glu Phe 
115 12 O 125 
Gly Lieu Lys Ile Ser Phe Val Asp Cys Ser Lys Ile Llys Lieu. Lieu. Glu 
13 O 135 14 O 
Ala Ala Ile Thr Pro Glu Thir Lys Lieu Val Trp Ile Glu Thr Pro Thr 
145 150 155 160 
Asn Pro Thr Glin Llys Val Ile Asp Ile Glu Ala Cys Ala His Ile Val 
1.65 17O 17s 
His Llys His Gly Asp Ile Ile Leu Val Val Asp Asn Thr Phe Met Ser 
18O 185 19 O 
Pro Tyr Phe Glin Arg Pro Leu Ala Leu Gly Ala Asp Ile Cys Met Tyr 
195 2OO 2O5 
Ser Ala Thr Lys Tyr Met Asn Gly His Ser Asp Val Val Ile Gly Lieu. 
21 O 215 22O 
Val Ser Val Asn. Cys Glu Ser Lieu. His Asn Arg Lieu. Arg Phe Lieu. Glin 
225 23 O 235 24 O 
Asn Ser Lieu. Gly Ala Val Pro Ser Pro Ile Asp Cys Tyr Lieu. Cys Asn 
245 250 255 
Arg Gly Lieu Lys Thr Lieu. His Val Arg Met Glu Arg His Phe Lys Asn 
26 O 265 27 O 
Gly Met Ala Val Ala Glin Phe Lieu. Glu Ser Asn Pro Trp Val Glu Lys 
27s 28O 285 
Val Ile Tyr Pro Gly Lieu Pro Ser His Pro Gln His Glu Lieu Val Lys 
29 O 295 3 OO 
Arg Glin Cys Thr Gly Cys Gly Gly Met Val Thr Phe Tyr Ile Lys Gly 
3. OS 310 315 32O 
Thir Lieu Gln His Ala Glu Ile Phe Lieu Lys Asn Lieu Lys Lieu. Phe Thr 
3.25 330 335 
Lieu Ala Val Ser Lieu. Gly Gly Phe Glu Ser Lieu Ala Glu Lieu Pro Ala 
34 O 345 35. O 
Ser Met Thr His Ala Ser Val Lieu Lys Asn Asp Arg Asp Val Lieu. Gly 
355 360 365 
Ile Ser Asp Thir Lieu. Ile Arg Lieu. Ser Val Gly Lieu. Glu Asp Glu Glu 
37 O 375 38O 
Asp Lieu. Lieu. Glu Asp Lieu. Asp Glin Ala Lieu Lys Ala Ala His Pro Pro 
385 390 395 4 OO 
Ser Gly Ser His Ser 
4 OS 
<210s, SEQ ID NO 26 
&211s LENGTH: 405 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic polypeptide 
<4 OOs, SEQUENCE: 26 
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What is claimed is: 
1. An isolated, modified human cystathionine-y-lyase 
(CGL) enzyme having at least the following Substitutions 
relative to a native human CGL amino acid sequence (see 
SEQ ID NO: 1), said substitutions selected from (a) E59N, 
S63L, L91M, R119L, K268R, T311G, E339V and I353S: 
(b) E59I, S63L, L91M, R119L, K268R, T311G, E339V and 
I353S; (c) E59N, S63L, L91M, R119A, K268R, T311G, 
E339V and I353S; and (d) E59I, S63L, L91M, R119A, 
K268R, T311G, E339V and I353S. 
2. The enzyme of claim 1, having at least the Substitutions 
E59N, S63L, L91M, R119L, K268R, T311G, E339V and 
I353S. 
3. The enzyme of claim 1, having at least the substitutions 
E59I, S63L, L91M, R119L, K268R, T311G, E339V and 
I353S. 
4. The enzyme of claim 1, having at least the Substitutions 
E59N, S63L, L91M, R119A, K268R, T311G, E339V and 
I353S. 
5. The enzyme of claim 1, having at least the substitutions 
E59I, S63L, L91M, R119A, K268R, T311G, E339V and 
I353S. 
6. The enzyme of claim 1, further comprising a heterolo 
gous peptide segment. 
7. The enzyme of claim 6, wherein the heterologous 
peptide segment is an XTEN peptide, an IgGFc, an albumin, 
or an albumin binding peptide. 
8. The enzyme of claim 1, wherein the enzyme is coupled 
to polyethylene glycol (PEG). 
9. The enzyme of claim 8, wherein the enzyme is coupled 






10. A pharmaceutical formulation comprising the enzyme 
of claim 1 in a pharmaceutically acceptable carrier. 
11. A method of treating a tumor cell or Subject having a 
tumor cell comprising administering to the tumor cell or the 
subject the formulation of claim 10. 
12. The method of claim 11, wherein the subject is 
maintained on a methionine restricted diet. 
13. The method of claim 11, wherein the subject is 
maintained on a normal diet. 
14. The method of claim 11, wherein the subject is a 
human patient. 
15. The method of claim 11, wherein the formulation is 
administered intravenously, intradermally, intraarterially, 
intraperitoneally, intralesionally, intracranially, intraarticu 
larly, intraprostatically, intrapleurally, intratracheally, 
intraocularly, intranasally, intravitreally, intravaginally, 
intrarectally, intramuscularly, Subcutaneously, Subconjuncti 
val, intravesicularly, mucosally, intrapericardially, 
intraumbilically, orally, by inhalation, by injection, by infu 
Sion, by continuous infusion, by localized perfusion bathing 
target cells directly, via a catheter, or via a lavage. 
16. The method of claim 11, wherein the formulation is 
administered to a nutrient medium of the tumor cell. 
17. The method of claim 16, wherein the nutrient medium 
is blood, lymphatic fluid, or spinal fluid. 
18. The method of claim 11, further comprising admin 
istering at least a second anticancer therapy to the Subject. 
19. The method of claim 18, wherein the second antican 
cer therapy is a Surgical therapy, chemotherapy, radiation 
therapy, cryotherapy, hormone therapy, immunotherapy or 
cytokine therapy. 
